

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Chronic respiratory health risk associated with powdered toner exposure in the longitudinal observation of occupationally exposed Japanese workers

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022049
Article Type:	Research
Date Submitted by the Author:	01-Feb-2018
Complete List of Authors:	Nakadate, Toshio; Showa Daigaku Daigakuin Igaku Kenkyuka, Hygiene & Preventive Medicine Yamano, Yuko; Showa Daigaku Daigakuin Igaku Kenkyuka, Hygiene & Preventive Medicine Shinagawa-ku, Tokyo, JP Yamauchi, Takenori; Showa Daigaku Daigakuin Igaku Kenkyuka, Hygiene & Preventive Medicine Okubo, Shigeko; Showa Daigaku Daigakuin Igaku Kenkyuka, Hygiene & Preventive Medicine Nagashima, Daichi; Showa Daigaku Daigakuin Igaku Kenkyuka, Hygiene & Preventive Medicine
Keywords:	EPIDEMIOLOGY, OCCUPATIONAL & INDUSTRIAL MEDICINE, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Chronic respiratory health risk associated with powdered toner exposure in the**  
5  
6 **longitudinal observation of occupationally exposed Japanese workers**  
7  
8  
9  
10

11 Toshio Nakadate(1), Yuko Yamano(1), Takenori Yamauchi(1), Shigeko Okubo(1), Daichi  
12  
13  
14  
15 Nagashima(1)  
16

17 (1) Department of Hygiene and Preventive Medicine, Showa University School of Medicine,  
18  
19  
20 Tokyo, Japan  
21  
22  
23  
24  
25

26 Corresponding author: Toshio Nakadate  
27

28  
29 Department of Hygiene and Preventive Medicine,  
30

31 Showa University School of Medicine  
32

33  
34 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan  
35

36  
37 e-mail: nakadate@med.showa-u.ac.jp  
38

39  
40 Tel: +81-3-3784-8137 Fax: +81-3-3784-8251  
41  
42  
43  
44  
45

46 Word count  
47

48  
49 Abstract: 256  
50

51 Text (Introduction, Methods, Results, Discussion, Conclusion): 4227  
52  
53

54 Table: 5  
55  
56  
57

References: 21

For peer review only

**Abstract**

**Objective:** We aimed to estimate the chronic health risk to humans associated with routine toner dust exposure in copier-industry workers under current actual work conditions, since little epidemiological evidence exists regarding the chronic respiratory effects of inhaled powdered toner exposure in humans.

**Design:** A prospective observational cohort study of occupational population.

**Methods:** Changes in chest radiogram, spirometry measurements, and serum and urine biomarkers of biomedical responses to extrinsic stress, as well as subjective symptoms were longitudinally observed for up to 10 years in Japanese copier-industry workers responsible for the manufacturing, maintenance or recycling of powdered toner or toner-using machines. A total of 694 subjects who did not change their work category during the follow-up and were free from chronic respiratory diseases at the baseline survey provided reliable results on at least 3 survey occasions during 3 years or more of follow-up.

**Results:** Typical fibrosis findings associated with pneumoconiosis was not observed on chest radiograms. No significant differences associated with toner exposure were noted in the frequency of new incidence of either non-specific findings on chest radiogram or serum fibrosis biomarkers (KL6 and SPD). However the exposed subjects tended to show increases in the frequency of respiratory symptoms and reduced spirometry results during the follow-up compared with the control group, although significant differences were only seen in chronic

1  
2  
3  
4 cough.  
5

6 **Conclusions:** Under the current reasonably controlled work environmental conditions, lung  
7  
8 fibrotic changes caused by inhaled dust exposure, including powdered toner, appear to be  
9  
10 relatively uncommon; however, nonspecific temporal irritation causing subjective symptoms  
11  
12 and inflammatory responses might exist.  
13  
14  
15  
16  
17  
18  
19

20 Key words: Dusts, Longitudinal studies, Respiratory, Epidemiology  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- An occupational cohort of workers in business machine industry exposed to printing toner dust in various types of work was followed for up to 10 years regarding their respiratory health status on an annual basis, mainly focusing on lung fibrotic changes.
- The incidence of newly emerging lung fibrotic changes was compared between the exposed workers and the non-exposed controls using wide-range health outcomes including chest X-ray findings, lung function results, and serum and urine biomarkers, as well as subjective symptoms.
- The total dust exposure during toner handling was measured in a representative sample of workers, but the fraction of toner particles in the whole dust exposure cannot be estimated accurately.
- Conventional chest radiography was utilized to evaluate lung fibrotic changes in an epidemiological research setting; however, computed tomography (CT) might have been more sensitive to early minimal fibrotic changes.
- Healthy worker bias might exist because some portion of the cohort ceased participation during the follow-up due to resigning, retiring, or transferring, although no toner-related health problems, such as lung fibrosis, were reported among these subjects.

## Introduction

Possible harmful effects of inhaled photocopier toner dust have been a matter of concern since the publication of several case reports suggesting the existence of toner-related pulmonary disorders [1][2][3]. However, little evidence is available regarding the potential for toner dust inhalation in occupational and general home environments where photocopier machines and laser printing devices are in use.

We reported the results of a cross-sectional study of toner-handling workers engaged in several types of toner exposure work [4]. Although the results suggested the limited possibility of adverse effects due to toner dust inhalation, it was also suggested that a study with longitudinal design would be useful for a more detailed examination of the hypothesized association between toner dust exposure and adverse health effects under current actual work conditions.

We therefore conducted a longitudinal study of toner-handling workers for 10 years in a business machine-producing company and affiliated companies involved in maintaining and recycling these machines in order to obtain longitudinal evidence to determine a possible health risk associated with a practical level of toner dust exposure under current actual work conditions, with particular focus on chronic fibrotic changes in the lungs.

This is the first report of this study and mainly presents the results of analyses of the possible chronic health effects, including lung fibrotic changes as the principal research target,



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

associated with toner dust exposure under current actual work conditions based on  
longitudinally observed health data.

For peer review only

## Methods

### *Subjects*

The subjects were employees of seven branches of a group of companies that produced, maintained, and recycled photocopiers, laser printers, and related products for printing with the use of powdered toner. We identified four categories of toner-handling work among the subjects. Toner production (TPD) represents work associated with any process in the course to producing powdered toner, such as mixing and molding raw materials, crushing toner mass, and filling and packing the products. Designing and development of machines (DDM) represents work associated with developing new models of toner-using business machines, in which various types of toner-handling procedures are involved. Maintenance (MTN) represents the work associated with maintaining photocopiers and laser printers in users' offices and homes. Recycling (RCL) represents work associated with processing recycled toner cartridges.

The survey on the health status of the subjects started in the fall of 2003 and was repeated until 2013 basically on an annual basis in the same manner as the first one in 2003. Throughout the entire study period, a total of 1176 toner handling workers (587 for TPD, 207 for DDM, 346 for MTN, and 36 for RCL) participated in at least one of these surveys. However, some participants ceased participation during an early stage of the study for various reasons other than toner-related health problems (e.g. resigning, retiring, or transferring), and

1  
2  
3  
4 others started participating in a later stage of the study. Therefore, we defined the subjects  
5  
6 with a sufficient follow-up duration for a longitudinal data analysis in this paper as those who  
7  
8 started participating by the spring of 2005 and were followed-up for three years or more with  
9  
10 at least three surveys throughout the entire study period. In addition, subjects were those who  
11  
12 had not changed their work category (concerning the presence or absence of toner handling)  
13  
14 during their follow-up.  
15  
16  
17  
18  
19

20 The number of toner workers who met the above criteria was 489. As a reference  
21  
22 population for comparison with these toner-handling workers, an additional 309 control  
23  
24 subjects who had never participated in any types of toner-handling work described above also  
25  
26 participated in this study by the spring of 2005. Among them, the 221 who met the same  
27  
28 criteria as exposed workers stated above were analyzed. Control subjects were recruited at  
29  
30 each participating branch and amounted to roughly half the number of toner-handling  
31  
32 workers.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 *Health status indices*

44  
45  
46 Subjects' health status was evaluated on an annual basis from various health-related aspects  
47  
48 using physiological, biochemical, and radiographic examination tools as well as via the  
49  
50 assessment of subjective symptoms and clinical signs. This evaluation focused mainly on  
51  
52 chronic respiratory deterioration, including pulmonary fibrotic conditions, and biological  
53  
54  
55  
56

1  
2  
3  
4 responses to inhaled potentially harmful substances. Standardized methods were utilized for  
5  
6 health status measurement to keep the measurement bias as small as possible. The biomedical  
7  
8 indices examined in this study are described below.  
9  
10

### 11 12 13 14 15 *Chest X-ray findings*

16  
17 Chest radiography was carried out to obtain a standardized anterior-posterior X-ray film by  
18  
19 using prescribed standard procedures to detect mineral-dust pneumoconiosis in Japan [5].  
20  
21 Each X-ray film was read by one of three readers with sufficient experience in the  
22  
23 radiographic diagnosis of pneumoconiosis while referencing the standard films for the  
24  
25 diagnosis [6]. The readers were privy to no information regarding the exposure status of the  
26  
27 subjects. The severity of fibrotic findings in the lung fields was classified into 12 grades,  
28  
29 from 0/- to 3/+, according to the distribution and density of the small opacities. This  
30  
31 classification was compatible with that of the International Labor Organization (ILO) [7].  
32  
33 However, we noted none of the fibrotic findings typically observed in mineral dust  
34  
35 pneumoconiosis cases with 1/1 or a more severe grade profusion during early surveys.  
36  
37 Therefore, we additionally recorded mild, non-specific findings, such as sparse irregular  
38  
39 opacity, unclear interstitial shadow, or disrupted vascular shadow in radiographs. These  
40  
41 findings were not only potentially related to early effects of toner toxicity but also might be  
42  
43 caused by acute or sub-acute non-specific irritation or infection, which might be reversible.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

### *Questionnaire survey*

Detailed information regarding respiratory symptoms, allergic symptoms, past and present medical history, and lifetime smoking history was obtained using a translated version of a self-administered questionnaire standardized by the American Thoracic Society (ATS-DLD-78A) [8], with slight modification and several additional questions on allergies of the eye, nose, and skin. The responses were certified by several trained interviewers, and supplemental interviews were held when necessary. The lifetime work history was also confirmed during this interview.

### *Spirometry*

Subjects were asked to repeat the forced expiratory maneuver up to a maximum of five times in the standing position in order to obtain acceptable and reproducible spirometry results. The mechanical specifications of the spirometer used (DISCOM-21FX2; CHEST Co. Ltd., Tokyo, Japan) met the standards stipulated by ATS [9]. Routine BTPS correction and back-extrapolation were carried out. The calibration of the spirometer, spirometry measurements, and evaluation of the results were based on prescribed procedures described in detail elsewhere [10].

The percent predicted values standardized on sex, age, and height were calculated for

1  
2  
3  
4 FVC (%FVC) and FEV1 (%FEV1) in each subject based on the prediction equations  
5  
6 published by the Japan Thoracic Society [11]. We also calculated the percentage FEV1 by  
7  
8 FVC (FEV1%). The values of %FVC and %FEV1 were defined as reduced when they were  
9  
10 smaller than 80%. Similarly, FEV1% was considered to be reduced if it was less than 70%.  
11  
12  
13  
14 All figures were calculated from the best maneuver yielding the largest sum of FVC and  
15  
16 FEV1 for each subject [12].  
17  
18  
19  
20  
21  
22

### 23 *Serum and urine biomarkers*

24  
25  
26 Peripheral venous blood and urine (10 and 20 ml, respectively) were obtained from each  
27  
28 subject at the time of every survey. Serum was immediately separated from whole blood  
29  
30 sample using a routine procedure. Then, serum and urine samples were deeply frozen at  
31  
32 -80 °C until analyses were carried out.  
33  
34  
35  
36

37  
38 As the indices of biological responses to inhaled extrinsic irritants like toner particles,  
39  
40 we employed the following biomarkers: highly sensitive C-reactive protein (CRP),  
41  
42 non-specific immunoglobulin E (IgE), sialylated carbohydrate antigen KL-6 (KL6), and lung  
43  
44 surfactant protein D (SPD) in serum, and 8-hydroxy deoxy guanosine (8OHdG) in urine. In  
45  
46 Japan, serum CRP, IgE, KL6, and SPD levels are routine clinical laboratory test items  
47  
48 assessed in common medical practice. The analyses of those results were therefore carried out  
49  
50 according to the appropriate Standard Operation Procedures (SOP) in SRL Inc., Tokyo.,  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 Japan which has been providing high quality testing under the certification of the Japan  
5  
6 Accreditation Board, a public service juridical foundation for ensuring the reliability of  
7  
8 clinical laboratory testing in Japan.  
9  
10

11  
12 Urine 8OHdG was measured using an ELISA kit (New 8OHdG Check ELISA Kit;  
13  
14 Japan Institute for the Control of Aging) and was adjusted for urine condensation using the  
15  
16 urine creatinine concentration as the denominator.  
17  
18

19  
20 The result of the measurement of each index was judged to be out of the normal range  
21  
22 when the value exceeded the following figures: 1500 ng/ml for CRP, 173 IU/ml for IgE,  
23  
24 500 U/ml for KL6, 110 ng/ml for SPD, and 20 ng/mg creatinine for 8OHdG.  
25  
26  
27  
28  
29  
30

### 31 32 *Exposure assessment*

33  
34 We directly measured the personal exposure levels in individual toner-handling workers.  
35  
36  
37 Workers were asked to wear a portable personal dust sampler that continuously sampled the  
38  
39 air in the workplace environment to collect suspended dust throughout a given period of  
40  
41 toner-related work. The concentration of total and respirable dust exposed to the workers was  
42  
43 calculated as a time-weighted average value for 8 h (TWA-8h) based on the amount of dust  
44  
45 collected on the filter and the total volume of air inspired by the sampling pump.  
46  
47  
48 Measurements were conducted basically twice a year for at least 5 workers in each  
49  
50 toner-handling procedure, yielding a total of 2042 measurements (1751 for TPD, 81 for DDM,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 88 for MTN, and 122 for RCL) throughout the study period. Those values obtained were  
5  
6  
7 evaluated with reference to the recommendations by the Japan Association of Industrial  
8  
9 Health (JAIH) [13]. We were unable to obtain reliable estimates of the amount of toner dust  
10  
11  
12 fraction in the whole dust cluster collected on the sampling filter, mainly because of large  
13  
14  
15 variability of the values depending on the types of toner handled.  
16  
17  
18  
19

### 20 *Analyses*

- 21 • Cross-sectional evaluation of baseline data

22  
23  
24 For each subject, we considered the results obtained in the first year of participation as the  
25  
26  
27 baseline data, indicating the condition at the beginning of the longitudinal observation of this  
28  
29  
30 study. The relative frequency of subjects with positive results was calculated for each  
31  
32  
33 health-related item described above (prevalence) and compared statistically between the  
34  
35  
36 exposed subjects as a whole and the control subjects.  
37  
38  
39  
40  
41  
42

- 43 • Longitudinal evaluation of chronic fibrotic findings

44  
45  
46 For the longitudinal analysis, we mainly focused on the results associated with chronic  
47  
48  
49 respiratory toxicity, including the fibrotic potential of toner dust inhalation exposure. To this  
50  
51  
52 end, we analyzed the changes in chest radiographic findings during the follow-up period. We  
53  
54  
55 also used three pulmonary function indices (%FVC, %FEV1, and FEV1%) and two serum  
56  
57  
58  
59  
60



1  
2  
3  
4 biomarkers (KL6 and SPD, both of which are recognized as useful markers of active-phase  
5  
6 fibrotic conditions in the lungs) [14]. In addition, we selected three chronic respiratory  
7  
8 symptoms associated with chronic respiratory diseases, such as fibrotic lung changes, namely  
9  
10 chronic cough, chronic phlegm, and breathlessness. Chronic cough, as well as chronic  
11  
12 phlegm, was considered to be present when the symptom existed for three months or more in  
13  
14 a year. Breathlessness was considered to be present when a subject walked slower than their  
15  
16 counterparts of the same age on level ground.  
17  
18  
19  
20  
21  
22

23  
24 In the longitudinal data analysis, we evaluated the frequency of abnormalities that  
25  
26 newly emerged during the follow-up observation (incidence). Abnormalities were considered  
27  
28 to be present when the respiratory symptom or the X-ray findings were newly noted or when  
29  
30 the pulmonary function or biomarker values exceeded the normal range during follow-up.  
31  
32 Therefore, those subjects who already had abnormalities at their baseline survey were  
33  
34 excluded from the longitudinal data analysis.  
35  
36  
37  
38  
39  
40  
41  
42

### 43 *Statistical analyses*

44  
45  
46 For comparisons by exposure categories, the chi-squared test and Fisher's exact test as well as  
47  
48 a multiple logistic regression analysis were performed for categorical variables, and a simple  
49  
50 *t*-test and an analysis of covariance were performed for numeric variables, with the alpha  
51  
52 error level set at 0.05. All statistical tests and estimations were carried out using the SAS  
53  
54  
55  
56

1  
2  
3  
4 statistical package on a personal computer (PC-SAS Version 9.2; SAS Institute Inc., NC,  
5  
6 U.S.A.).  
7  
8  
9  
10

11  
12 *Ethical considerations*  
13

14  
15 The objectives and outline of the study were explained to the subjects at the beginning of the  
16  
17 study, and written informed consent was obtained from each participant. All information  
18  
19 obtained in this study was handled in accordance with the guidelines for epidemiological  
20  
21 studies authorized in Japan [15]. This study was conducted under the approval of the  
22  
23 Institutional Review Board on Medical Ethics of Showa University School of Medicine  
24  
25  
26  
27  
28  
29 (Authorization No. 201).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

As stated earlier, we selected 710 workers (489 exposed and 221 controls) as the subjects for this longitudinal data analysis. Among them, 16 subjects reported that they had suffered from chronic respiratory diseases prior to the beginning of this study (chronic obstructive pulmonary disease and/or pulmonary tuberculosis). These subjects were therefore excluded, and the remaining 694 subjects were ultimately analyzed. The average number of surveys in which those subjects participated was 6.8, and the average follow-up duration (elapsed time from the first observation to the final one) was 7.4 years. No significant difference was observed in those average values between the exposed and control groups.

Several background characteristics at the baseline point were compared among the exposure categories in Table 1. The male to female ratio was comparable between the exposed and control groups, although the absolute number of female subjects was quite small compared to males. Significant differences were observed between the exposed and control groups in mean age and smoking habit classification at the baseline survey, with the exposed group being younger and more likely to smoke than the controls. Seventy-six of 360 current smokers at baseline quit smoking during their follow-up period, whereas only 1 out of 220 never smokers at the point of baseline started smoking during the follow-up. As for body size, the mean values of standing height and body mass index (BMI) were comparable between the exposed and control groups.

1  
2  
3  
4 Table 2 summarizes the result of personal exposure measurement during the entire  
5  
6 study period, showing the median and the 10th and 90th percentile values of the TWA-8h  
7  
8 concentration of total and respirable dust exposure. The TPD and RCL workers tended to  
9  
10 show higher percentile values both in the total and respirable TWA-8h than the DDM and  
11  
12 MTN workers. As suggested by those summary percentile values, the individual TWA-8h  
13  
14 values distributed across a rather wide range, and some of them exceeded the permissible  
15  
16 limit recommended by JAIH (4 mg/m<sup>3</sup> as total and 1 mg/m<sup>3</sup> as respirable carbon black dust,  
17  
18 and 8 mg/m<sup>3</sup> as total and 2 mg/m<sup>3</sup> as respirable general dust) [13]. However, the overall  
19  
20 median TWA-8h values of both total and respirable dust were well below the JAIH  
21  
22 recommendations, even among the TPD and RCL workers. No marked changes were  
23  
24 observed in the percentile values during the 10-year follow-up, suggesting that the work  
25  
26 environment was relatively stable throughout the study period in terms of dust exposure to  
27  
28 the workers as a whole.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Table 3 summarizes the prevalence of the biomedical indices studied at the baseline  
41  
42 survey according to the exposure categories. The odds ratios (ORs) and their 95% confidence  
43  
44 intervals (CIs) of the exposed to the control group are also shown after adjustment for  
45  
46 possible confounding variables. The exposed group tended to show higher prevalence in  
47  
48 respiratory symptom indices, although significant differences were observed only in chronic  
49  
50 phlegm and wheeze grade 2. The prevalence values for CRP and IgE abnormalities were also  
51  
52  
53  
54  
55  
56

1  
2  
3 significantly larger in the exposed group than in the control group, although the results of  
4  
5  
6 KL6 and SPD were comparable between the two groups. The difference in CRP remained  
7  
8  
9 significant even after adjustment for BMI, a well-known contributor to the serum CRP level.  
10  
11  
12 Subjects with %FVC, %FEV1 or FEV1% values outside of the reference range were  
13  
14  
15 relatively rare. There were no cases of clear pneumoconiosis with 1/1 or a more severe grade  
16  
17  
18 on baseline chest X-ray films of the subjects analyzed, although non-specific findings were  
19  
20  
21 noted in 3.4% of the exposed and 1.8% of the control subjects at baseline. No significant  
22  
23  
24 difference between the two groups was noted in the prevalence at baseline of either the  
25  
26  
27 pulmonary function or chest X-ray indices.  
28

29  
30 Table 4 compared the frequency of newly emerging abnormalities observed during the  
31  
32 follow-up period between the exposed and the control groups for selected biomedical indices  
33  
34  
35 in order to examine the degree of chronic respiratory deterioration, including lung fibrotic  
36  
37  
38 changes. After carefully evaluating the chest X-ray films accumulated during the follow-up  
39  
40  
41 period, we observed no cases with 1/1 or a more severe grade of pneumoconiosis. In addition,  
42  
43  
44 the incidence of non-specific findings during the follow-up was comparable between the  
45  
46  
47 exposed and control groups. Furthermore, two clinically useful biomarkers of lung fibrosis  
48  
49  
50 (KL6 and SPD) showed rather low incidence values for newly emerging abnormalities, which  
51  
52  
53 were comparable between the exposed and control groups. However, regarding symptoms  
54  
55  
56 and the pulmonary function, the exposed group tended to have a higher incidence of  
57  
58  
59  
60

1  
2  
3  
4 abnormalities more frequently than the control group. The ORs estimated by logistic  
5  
6 regression analyses mostly exceeded 1.5, and after adjustment for age and smoking status  
7  
8 during the follow-up period, chronic cough emerged significantly more frequently in the  
9  
10 exposed subjects than in the control group.  
11  
12  
13

14  
15 Table 5 summarizes the significant independent contribution of confounding factors in  
16  
17 the multivariate analyses described in Tables 3 and 4 as estimated ORs for the health-related  
18  
19 outcomes. Only statistically significant results are presented with their 95% CIs. Smoking  
20  
21 was considered to increase the incidence of chronic phlegm, SPD abnormality, and  
22  
23 reduced %FVC and %FEV1 during follow-up, as well as the prevalence of many symptoms  
24  
25 and a reduced pulmonary function at baseline. Similar increases in ORs with age were also  
26  
27 observed for the incidence during the follow-up and the prevalence at baseline of some of the  
28  
29 examined indices. A clear independent association between serum CRP abnormalities and  
30  
31 obesity was also observed.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

Photocopiers and laser printers using powdered toner are widely used in offices and homes, but the powdered toner for printing and emissions from these machines may become air pollutants in office and home environments [16][17]. McGarry et al. reported the condition of particulate air pollution resulting from the use of laser printers in several actual office environments [18]. However, only a few epidemiological reports have studied the possible health effects of everyday office pollutants, including toner dust used in photocopiers and laser printers. We previously reported [4] the results of an epidemiologic study on the health-related parameters associated with toner-handling procedures in Japanese workers. There seemed to be only a limited possibility that cumulative toner exposure could cause severe chronic health disorders, as long as a properly-controlled work environment was maintained. Khatri et al. [19] conducted a human volunteer exposure study in an actual current office environment and found that several biomarkers, including 8OHdG as a marker of oxidative stress [20], changed in relation with the particulate air pollutants emitted by photocopiers and laser printers, although those changes were acute or sub-acute and not chronic in nature. However, the results reported thus far were all obtained in cross-sectional studies, and longitudinal study results are needed to fully examine the health impact of particulate air pollutants associated with office machines, as far as chronic health effects are concerned. Quite recently, Ikegami et al. [21] reported no adverse health effects due to toner

1  
2  
3  
4 dust exposure in their longitudinal observation of Japanese toner-handling workers in what  
5  
6 seems to our knowledge to be the only longitudinal study reported thus far. Therefore, as a  
7  
8 subsequent study of our cross-sectional one mentioned above [4], we conducted a  
9  
10 longitudinal study to further evaluate the possible health effects of toner dust exposure,  
11  
12 focusing mainly on the chronic respiratory effects, such as lung fibrotic changes. To  
13  
14 determine the actual risk in the current real-world environment, we studied an actual working  
15  
16 population. Personal exposure measurement results showed that the current level of exposure  
17  
18 to total and respirable dust in toner-handling workers was on average well below the  
19  
20 permissible exposure levels of general mineral dust and carbon black dust recommended by  
21  
22 JAIH [13], even among TPD and RCL workers, in whom relatively high exposure was  
23  
24 observed. We also used several biomedical indices to detect possible harmful effects on the  
25  
26 respiratory system: namely imaging findings by chest X-ray, KL6 and SPD levels in serum as  
27  
28 clinically utilized biomarkers on lung fibrosis, spirometry results to evaluate the lung  
29  
30 functional status, and subjective symptoms obtained through standardized methods.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 In a cross-sectional analysis of the baseline results, the exposed group tended to have  
44  
45 subjective symptoms more frequently than in the control group, and similar group differences  
46  
47 were observed in the frequency of abnormal values in the majority of the biomedical indices  
48  
49 examined. In addition, the difference between the two groups reached a statistically  
50  
51 significant level in several items, even after controlling for confounders. This tendency was  
52  
53  
54  
55  
56



1  
2  
3  
4 basically consistent with what we had previously reported, with exposed workers  
5  
6 complaining of symptoms more frequently than control workers despite having a comparable  
7  
8 frequency of pulmonary function and chest radiography abnormalities. However, the  
9  
10 cross-sectional evaluation at the baseline might have been influenced by a number of factors  
11  
12 prior to the start of this study. Therefore, newly emerging abnormalities during follow-up  
13  
14 should be examined in subjects without any abnormalities at the baseline observation, as far  
15  
16 as the chronic health effects are concerned. One interesting finding of the cross-sectional  
17  
18 analysis was the higher prevalence of CRP abnormalities, a sensitive marker of acute  
19  
20 inflammatory status in the body, among the exposed subjects compared with control subjects.  
21  
22 It seems unlikely that the elevated CRP values were significantly influenced by events in the  
23  
24 past due to its nature as an acute inflammatory biomarker. In addition, the difference seemed  
25  
26 to be independent of inflammatory conditions caused by obesity or smoking, as both were  
27  
28 used as adjustment factors in the logistic regression model. These findings suggest that acute  
29  
30 inflammatory conditions might be associated with current toner exposure. At the same time,  
31  
32 an increase in the serum IgE level was also frequently found in the exposed subjects. In Japan,  
33  
34 an allergy to cedar pollen is commonly observed every spring, so cedar pollenosis may be  
35  
36 related to the findings for CRP and IgE.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 In the longitudinal analyses of biomedical indices, we evaluated the frequency of a  
52  
53 newly emerging abnormality during the follow-up period by excluding the subjects from the  
54  
55  
56

1  
2  
3  
4 analysis if they already had the finding at baseline. Among the indices associated with lung  
5  
6 fibrotic changes, we found closely similar results between the exposed and control groups  
7  
8 regarding the new incidence of chest radiographic findings and serum biomarker  
9  
10 abnormalities. These results suggest that the fibrogenic potential of dust exposure associated  
11  
12 with toner-handling work seems to be minimal, if any at all, as far as the current working  
13  
14 environment is concerned.  
15  
16  
17  
18  
19

20  
21 In contrast, the estimated ORs for %FVC and FEV1% abnormality adjusted for  
22  
23 confounders showed relatively large values exceeding 1.5, although their increases were not  
24  
25 statistically significant. However, it seems difficult to attribute certain biological or medical  
26  
27 reasons to the moderate but insignificant elevation in ORs for %FVC and FEV1%  
28  
29 abnormality because the incidence of reduced %FEV1 was comparable between the exposed  
30  
31 and control subjects. Some fluctuation around normal ranges might be partially responsible  
32  
33 for the observed elevation in OR values. In the case of chronic cough, the exposed group  
34  
35 showed a larger incidence than the control group. This finding was not associated with the  
36  
37 findings for chronic phlegm, which showed a comparable incidence after adjusting for the  
38  
39 significant contribution of smoking. This suggests that the significant increase in the rate of  
40  
41 chronic cough cannot be attributed to mucus hypersecretion. Given the findings at baseline  
42  
43 mentioned earlier, it might be possible to hypothesize that non-specific irritation leading to  
44  
45 subjective symptoms, fluctuation in the pulmonary function, and inflammatory response were  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 caused to some extent by exposure associated with toner-handling work.  
5

6  
7 Several limitations associated with the present study warrant mention. First, the  
8  
9 number of subjects of this study (694 in total) might be insufficient to detect minimal health  
10  
11 deteriorations. However, several well-established health risks were reconfirmed in this study,  
12  
13 including the increase in the incidence of mucus hypersecretion symptoms and the pulmonary  
14  
15 function deterioration due to smoking, as well as the increase in the incidence of non-specific  
16  
17 chest X-ray findings with age. A significant positive association between obesity and serum  
18  
19 CRP concentration was also observed. These results suggest that this study had a reasonably  
20  
21 sufficient sample size, at least for health risks at a generally detectable level, despite not  
22  
23 being highly sensitive. A meta-analysis of the studies with a common methodological basis  
24  
25 will be useful for detecting minimal effects of toner dust. Second, we obtained measurements  
26  
27 on personal exposure concentration for each work category as an exposure assessment.  
28  
29 However, the results showed large variability. In addition, we were unable to obtain reliable  
30  
31 data on the relative content of toner as a fraction of the whole dust sample. We therefore  
32  
33 cannot reliably estimate the amount of personal exposure to toner dust for each individual  
34  
35 subject. An analysis of the dose-response relationship will require a more precise exposure  
36  
37 assessment for toner dust. Third, we simply utilized conventional chest radiography and did  
38  
39 not use computed tomography (CT) to evaluate lung fibrotic changes, because we should  
40  
41 minimize the amount of X-rays that the participants were exposed to in an epidemiological  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 research setting. We were therefore unable to distinguish the non-specific findings in cases  
5  
6 where extremely-early-phase of toner-related changes might have been included. Advanced  
7  
8 radiography techniques will be useful for the more precise evaluation of lung fibrotic  
9  
10 deterioration caused by toner dust inhalation.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Conclusion

Under the current reasonably controlled work environmental conditions, lung fibrotic changes caused by inhaled dust exposure, including powdered toner, appear to be relatively uncommon; however, nonspecific temporal irritation causing subjective symptoms and inflammatory responses might exist. These longitudinal findings are consistent with the results observed in a cross-sectional study conducted previously.

## Acknowledgments

The authors thank all the subjects, investigators and survey staff who participated in this longitudinal study over 10 years.

## Footnotes

**Contributors:** TN designed the study; TN and YY executed the data collection in annual surveys; YY, TY, SO and DN contributed to the data preparation and analyses; TN wrote the initial manuscript. All of the authors contributed to the revision of the manuscript and approved the final form of the manuscript for submission.

**Funding:** This study was funded in part by Ricoh Co., Ltd., Japan.

**Competing interest:** The authors report no conflicts of interest for the submitted work.

**Data sharing statement:** No additional data available.

## References

- [1] Gallardo M, Romero P, Sanchez-Quevedo MC, Lopez-Caballero JJ. Siderosilicosis due to photocopier toner dust. *Lancet* 1994 Aug 6;344(8919):412-3.
- [2] Armbruster C, Dekan G, Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust. *Lancet* 1996 Sep 7;348(9028):690.
- [3] Wieriks J. Photocopier toner dust and lung disease. *Lancet* 1996 Nov 30;348(9040):1518-9.
- [4] Nakadate T, Yamano Y, Adachi C, Kikuchi Y, Nishiwaki Y, Nohara M, Satoh T, Omae K. A cross-sectional study of the respiratory health of workers handling printing toner dust. *Occup Env Med* 2006;63:244-9.
- [5] Department of Health and Safety. Ministry of Labour, Japan. Jintai Shinsa handbook (Pneumoconiosis examination handbook). Tokyo: Japan Safety and Health Association, 1978. (In Japanese)
- [6] Ministry of Labour, Japan. Jintai Hyoujun x-ray films (Standard x-ray films for diagnosis of pneumoconiosis). Tokyo: Japan Safety and Health Association, 1982. (In Japanese)
- [7] International Labour Organization. International Classification of Radiographs of Pneumoconioses (Revised, 2000). 2002.
- [8] Ferris BG. Epidemiology standardization project. *Am Rev Respir Dis* 1978;118(6, 2 of 2 parts):57-62.

1  
2  
3  
4 [9] American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir  
5  
6 Crit Care Med 1995;152:1107-36.  
7

8  
9 [10] Nakadate T, Aizawa Y, Yagami T, Zheng YQ, Kotani M. Change in obstructive  
10  
11 pulmonary function as a result of cumulative exposure to welding fumes as determined by  
12  
13 magnetopneumography in Japanese arc welders. Occup Environ Med 1998;55:673-7.  
14  
15

16  
17 [11] Committee on Pulmonary Physiology, Japan Society of Respiriology. Reference values  
18  
19 on spirometry and arterial blood gas pressure parameters in Japanese. April, 2001. (in  
20  
21 Japanese)  
22  
23

24  
25 [12] Nakadate T. Longitudinal observation of pulmonary function decline in male Japanese  
26  
27 workers: design, baseline results, and methodological considerations of handling pulmonary  
28  
29 function data. Ind Health 1998;36:305-11.  
30  
31

32  
33 [13] Japan Association of Industrial Health. Recommendation on threshold limit values,  
34  
35 Japan (2016). Sangyo Eiseigaku Zasshi 2016;58(5):181-212. (In Japanese)  
36  
37

38  
39 [14] Hermans C, Bernard A. Lung epithelium-specific proteins: characteristics and potential  
40  
41 applications as markers. Am J Respir Crit Care Med. 1999;159(2):646-78.  
42  
43

44  
45 [15] Ministry of Education, Culture, Sports, Science and Technology, and Ministry of Health,  
46  
47 Welfare, and Work, Japan. Ethical Guidelines for Epidemiological Studies. June 17, 2002.  
48  
49 <http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/ekigaku/0504sisin.html> (in Japanese)  
50  
51

52  
53 [16] He C, Morawska L, Taplin L. Particle emission characteristics of office printers.  
54  
55



1  
2  
3  
4 Environ Sci Technol 2007;41(17):6039-45.  
5

6 [17] Tang T, Hurras J, Gminski R, Mersch-Sundermann V. Fine and ultrafine particles emitted  
7 from laser printers as indoor air contaminants in German offices. Environ Sci Pollut Res Int  
8  
9 from laser printers as indoor air contaminants in German offices. Environ Sci Pollut Res Int  
10  
11 2012;19(9):3840-9.  
12  
13

14 [18] McGarry P, Morawska L, He C, Jayaratne R, Falk M, Tran Q, Wang H. Exposure to  
15 particles from laser printers operating within office workplaces. Environ Sci Technol. 2011  
16  
17 Aug 1;45(15):6444-52.  
18  
19  
20  
21  
22

23 [19] Khatri M, Bello D, Gaines P, Martin J, Pal AK, Gore R, Woskie S. Nanoparticles from  
24 photocopiers induce oxidative stress and upper respiratory tract inflammation in healthy  
25  
26 volunteers. Nanotoxicology 2013;7(5):1014-27.  
27  
28  
29  
30

31 [20] Irie M1, Tamae K, Iwamoto-Tanaka N, Kasai H. Occupational and lifestyle factors and  
32 urinary 8-hydroxydeoxyguanosine. Cancer Sci. 2005 ;96(9):600-6.  
33  
34  
35  
36

37 [21] Ikegami K, Hasegawa M, Ando H, Hata K, Kitamura H, Ogami A, Higashi T.

38 A cohort study of the acute and chronic respiratory effects of toner exposure among handlers:  
39  
40  
41  
42

43 A longitudinal analyses from 2004 to 2013.  
44  
45

46 Ind Health 2016; March 25.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Background characteristics of the subjects according to the exposure category.**

Characteristics	Category of exposure condition						<i>p</i> <sup>†</sup>
	Control	Exposed*	TPD	DDM	MTN	RCL	
Number surveyed	217	477	175	145	150	7	
Sex (M/F)	205/12	461/16	167/8	141/4	149/1	4/3	0.18
Age (years)	39.1(8.2)	34.1(8.1)	32.9(10.3)	35.4(6.5)	34.2(6.3)	32.4(7.6)	<0.0001
Height (cm)	170.1(6.6)	170.3(6.4)	169.0(6.1)	171.3(6.4)	171.4(6.4)	161.5(6.8)	0.63
BMI (kg/m <sup>2</sup> )	23.0(3.1)	23.0(3.7)	23.2(4.6)	22.4(2.6)	23.4(3.2)	19.9(1.5)	0.999
Smoking habit <sup>‡</sup>							0.026
Never	70(32)	150(31)	38(22)	69(48)	38(25)	5(71)	
Former	47(22)	67(14)	17(10)	26(18)	24(16)	0	
Current	100(46)	260(55)	120(68)	50(34)	88(59)	2(29)	

\* TPD: toner production, DDM: machine design and development, MTN: maintenance, RCL: recycling, BMI: body mass index

<sup>†</sup>Probability under the hypothesis that there are no differences between the control group and

1  
2  
3  
4 the exposed group as a whole.  
5

6 ‡Percentage of column total in parentheses.  
7  
8

9 Values are presented the number of subjects for sex and smoking habit and the arithmetic  
10  
11  
12 mean (standard deviations) for age, height, and BMI at the baseline survey.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 2. Exposure levels of toner-handling workers by their working category and year of measurement estimated by personal exposure measurements**

	Total dust (mg/m <sup>3</sup> )			Respirable dust (mg/m <sup>3</sup> )		
	10th	Median	90th	10th	Median	90th
	%ile		%ile	%ile		%ile
Total	0.08	0.49	2.38	0.03	0.05	0.36
Work category*						
TPD	0.09	0.5	2.14	0.03	0.09	0.35
DDM	0.04	0.08	0.38	0.03	0.03	0.04
MTN	0.07	0.17	0.8	0.03	0.03	0.15
RCL	0.51	1.46	5.6	0.02	0.04	0.64
Year of measurement						
2004	0.11	0.54	2.44	0.03	0.07	0.43
2005	0.07	0.43	1.96	0.03	0.05	0.3
2006	0.08	0.62	2.26	0.03	0.06	0.37
2007	0.1	0.74	3.34	0.03	0.05	0.47
2008	0.08	0.58	2.8	0.03	0.06	0.49

1							
2							
3							
4	2009	0.09	0.49	2.58	0.02	0.06	0.31
5							
6	2010	0.09	0.48	2.35	0.02	0.05	0.28
7							
8							
9	2011	0.08	0.44	1.96	0.02	0.06	0.37
10							
11							
12	2012	0.09	0.4	1.68	0.02	0.04	0.22
13							
14							
15	2013	0.06	0.26	1.82	0.02	0.04	0.16
16							
17							
18							
19							
20							
21							
22							
23							
24							
25							
26							
27							
28							
29							
30							
31							
32							
33							
34							
35							
36							
37							
38							
39							
40							
41							
42							
43							
44							
45							
46							
47							
48							
49							
50							
51							
52							
53							
54							
55							
56							
57							
58							
59							
60							

\* TPD: toner production, DDM: machine design and development, MTN: maintenance, RCL: recycling

Values are presented as the median and the 10th and 90th percentiles (%ile) for personal exposure measurement data.

**Table 3. The comparison of the baseline status in select biomedical indices at the point of the first examination for each subject between the exposed subjects as a whole and the controls**

Biomedical indices	Univariate analysis			Multivariate analysis	
	Exposed	Controls	<i>p</i> *	OR <sup>†</sup>	95%CI <sup>†</sup>
Respiratory symptoms <sup>‡</sup>					
Cough #1 (7A)	19.4	14.8	0.14	1.35	(0.85-2.14)
Cough #2 (7B)	14.8	11.1	0.19	1.41	(0.84-2.37)
Chronic cough (7E)	5.5	4.2	0.46	1.6	(0.70-3.64)
Phlegm #1 (8A)	23.7	20.4	0.34	1.23	(0.81-1.87)
Phlegm #2 (8B)	13.5	10.7	0.29	1.45	(0.85-2.48)
Chronic phlegm (8C)	8.9	4.2	0.03	2.62	(1.20-5.70)
Exacerbation (9A)	10.5	7	0.14	1.56	(0.84-2.91)
Wheeze #1 (10A1)	9.5	5.6	0.09	1.51	(0.76-2.99)
Wheeze #2 <sup>§</sup> (10A2)	2.7	0	0.01	-	-
Chronic Wheeze (10A3)	0	0	-	-	-
Breathlessness #1 (13A)	9.7	11.6	0.45	1	(0.58-1.73)

Breathlessness #2 <sup>§</sup> (13B)	2.2	1.4	0.76	2.27	(0.58-8.89)
Breathlessness #3 <sup>§</sup> (13C)	0.4	0.9	0.59	0.96	(0.13-7.20)
Biomarker abnormality					
CRP	12.0	6.0	0.02	2.02	(1.05-3.88)
IgE	31.7	20.8	0.003	1.66	(1.12-2.48)
8OHdG <sup>§</sup>	1.1	1.8	0.47	0.68	(0.17-2.78)
KL6 <sup>§</sup>	0.4	0	1	-	-
SPD	3.2	3.4	0.89	0.91	(0.35-2.37)
Reduced pulmonary function					
%FVC	5.3	4.2	0.55	1.07	(0.47-2.42)
%FEV1	8.4	4.7	0.08	1.97	(0.95-4.14)
FEV1% <sup>§</sup>	0.6	0.5	1	2.54	(0.25-25.6)
Chest X-ray findings					
Fibrotic change $\geq 1/1$	0	0	1	-	-
Non-specific findings	3.4	1.8	0.27	2.47	(0.78-7.81)

\* Probability under the hypothesis that there are no differences between the control group and exposed group as a whole examined by the chi-squared test or Fisher's exact probability method.

1  
2  
3  
4 † Odds ratio (OR) and its 95% confidence intervals (95% CI) of the exposed group to the  
5  
6 control group, regarding the positive findings at the baseline survey  
7

8  
9 ‡ The ATS-DLD-78A questionnaire code is shown in the parentheses  
10

11  
12 Fisher's exact probability method was applied.  
13

14  
15 # Grade of the severity of the symptom  
16

17  
18 The figures in the column of prevalence represent the proportion of subjects with symptoms  
19  
20 or positive findings in each index. The results of multivariate analyses were adjusted for the  
21  
22 age and smoking status of the subjects. Body mass index was also used as an adjustment  
23  
24 factor in the case of CRP.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 4. A comparison of the cumulative frequency of incidence in select biomedical indices associated with lung fibrotic changes that newly emerged during the follow-up period**

	Univariate analysis			Multivariate analysis	
	Incidence			Logistic regression model	
	Exposed	Controls	<i>p</i> *	OR <sup>†</sup>	95%CI <sup>†</sup>
Respiratory symptoms <sup>‡</sup>					
Chronic cough (7C)	11.3	6.3	0.04	2.26	(1.13-4.53)
Chronic phlegm (8C)	14	9.6	0.12	1.6	(0.91-2.83)
Breathlessness #2 (13B)	6	4.7	0.48	1.69	(0.73-3.94)
Serum biomarkers					
KL6 <sup>§</sup>	2.1	1.8	1	1.27	(0.38-4.29)
SPD	2.4	2.4	1	1.06	(0.34-3.28)
Pulmonary function					
%FVC	12.8	8.2	0.08	1.51	(0.83-2.73)
%FEV1	13.5	13.5	1	1.01	(0.60-1.70)
FEV1%	3.8	2.8	0.5	1.99	(0.75-5.30)

1  
2  
3  
4 Chest X-ray

5  
6 Non-specific findings            5.6            5.2            0.8            1.39            (0.65-2.97)  
7  
8  
9

10  
11  
12 \* Probability under the hypothesis that there are no differences between the control group and  
13  
14 exposed group as a whole examined by the chi-squared test or Fisher's exact probability  
15  
16 method  
17  
18

19  
20 † Odds ratio (OR) and its 95% confidence intervals (95% CI) of the exposed group to the  
21  
22 control group, regarding the newly emerging abnormalities of biomedical indices  
23  
24

25  
26 ‡ The ATS-DLD-78A questionnaire code is shown in the parentheses.  
27

28  
29 § Fisher's exact probability method was applied.  
30

31  
32 # Grade of the severity of the symptom  
33

34  
35 The figures in the column of incidence represent the proportion of subjects starting to show  
36  
37 symptoms or positive findings during the follow-up period among those who did not have the  
38  
39 symptom or positive finding at baseline. The results of multivariate analyses were adjusted  
40  
41 for the age and smoking status of the subjects.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Table 5. Independent contribution of confounding factors in the multivariate analyses of biomedical indices**

	Smoking		Age		BMI
	Prevalence*	Incidence†	Prevalence*	Incidence†	Prevalence*
	OR(95% CI)‡	OR(95% CI)‡	OR(95% Cis)‡	OR(95% CI)‡	OR(95% CI)‡
Cough #1 (7A)§	1.68(1.12-2.51)				
Cough #2 (7B)§	1.62(1.03-2.54)				
Chronic cough (7E)§	3.34(1.49-7.48)		1.63(1.08-2.45)		
Phlegm #1 (8A)§	2.38(1.63-3.47)				
Phlegm #2 (8B)§	2.62(1.60-4.29)		1.38(1.05-1.82)		
Chronic phlegm (8C)§	3.69(1.85-7.35)	1.80(1.10-2.96)	1.53(1.08-2.16)		

1			
2			
3			
4			
5			
6	Breathlessness #1 (13A) <sup>§</sup>	1.59(1.17-2.16)	
7			
8			
9	Breathlessness #2†(13B) <sup>§</sup>	2.64(1.36-5.12)	
10			
11	Breathlessness #3†(13C) <sup>§</sup>	5.62(1.51-20.85)	
12			
13			
14	CRP abnormality		1.32(1.17-1.49)
15			
16			
17	SPD abnormality	4.10(1.15-14.58)	
18			
19			
20	Reduced %FVC	3.13(1.09-8.97)	
21			
22			
23	Reduced %FEV1	3.82(1.38-10.58)	
24			
25			
26	Reduced FEV1%	3.92(1.20-12.87)	2.11(1.27-3.52)
27			
28	Non-specific X-ray		1.59(1.06-2.38)
29			
30			
31	findings		
32			
33			
34			
35			
36			
37	* An analysis of the prevalence at baseline.		
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

† An analysis of the new incidence during the follow-up observation

‡ Odds ratio (OR) and its 95% confidence intervals (95% CI) of the exposed group to the control group, regarding the prevalence and incidence of biomedical indices.

§ The ATS-DLD-78A questionnaire code is shown in the parentheses.

# Grade of the severity of the symptom

Values are presented as the OR (95% CI) estimated using the logistic regression models shown in Tables 3 and 4. Only statistically significant results are shown.

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies***

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6-7
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	8-9
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	10-13
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	10-13
Bias	9	Describe any efforts to address potential sources of bias	9, 10-12
Study size	10	Explain how the study size was arrived at	8-9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	14-15
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	15
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	8-9
		(e) Describe any sensitivity analyses	20, 41-43
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	17
		(b) Give reasons for non-participation at each stage	17
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	17-19, 32-38
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	17
Outcome data	15*	Report numbers of outcome events or summary measures over time	19-20, 39-40
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	19-20, 39-40
		(b) Report category boundaries when continuous variables were categorized	11, 13
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	20, 41-43
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	23-24
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	25-26
Generalisability	21	Discuss the generalisability (external validity) of the study results	
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	28

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Chronic respiratory health risk associated with powdered toner exposure in the longitudinal observation of occupationally exposed Japanese workers

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022049.R1
Article Type:	Research
Date Submitted by the Author:	11-Apr-2018
Complete List of Authors:	Nakadate, Toshio; Showa University Graduate School of Medicine School of Medicine, Hygiene, Public Health and Preventive Medicine Yamano, Yuko; Showa University Graduate School of Medicine School of Medicine, Hygiene, Public Health and Preventive Medicine Yamauchi, Takenori; Showa University Graduate School of Medicine School of Medicine, Hygiene, Public Health and Preventive Medicine Okubo, Shigeko; Showa University Graduate School of Medicine School of Medicine, Hygiene, Public Health and Preventive Medicine Nagashima, Daichi; Showa University Graduate School of Medicine School of Medicine, Hygiene, Public Health and Preventive Medicine
<b>Primary Subject Heading</b>:	Occupational and environmental medicine
Secondary Subject Heading:	Epidemiology, Respiratory medicine
Keywords:	EPIDEMIOLOGY, OCCUPATIONAL & INDUSTRIAL MEDICINE, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™  
Manuscripts





1  
2  
3  
4 **Chronic respiratory health risk associated with powdered toner exposure in the**  
5  
6 **longitudinal observation of occupationally exposed Japanese workers**  
7  
8  
9

10  
11  
12 Toshio Nakadate(1), Yuko Yamano(1), Takenori Yamauchi(1), Shigeko Okubo(1), Daichi  
13  
14  
15 Nagashima(1)  
16

17  
18 (1) Department of Hygiene and Preventive Medicine, Showa University School of Medicine,  
19  
20  
21 Tokyo, Japan  
22  
23  
24  
25

26 Corresponding author: Toshio Nakadate  
27

28  
29 Department of Hygiene and Preventive Medicine,  
30

31  
32 Showa University School of Medicine  
33

34  
35 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan  
36

37  
38 e-mail: nakadate@med.showa-u.ac.jp  
39

40  
41 Tel: +81-3-3784-8137 Fax: +81-3-3784-8251  
42  
43  
44  
45

46 Word count  
47

48  
49 Abstract: 276  
50

51  
52 Text (Introduction, Methods, Results, Discussion, Conclusion): 5158  
53

54  
55 Table: 5, Figure 2  
56

References: 28

For peer review only

**Abstract**

**Background:** Little epidemiological evidence exists regarding the chronic respiratory effects of inhaled powdered toner exposure in humans, although several case reports have suggested the existence of lung disorders that might be related to exposure to toner dust.

**Objective:** We aimed to estimate the chronic health risk to humans associated with routine toner dust exposure in copier-industry workers under current actual work conditions.

**Design:** A prospective observational cohort study of occupational population.

**Methods:** Changes in chest radiogram, spirometry measurements, and serum and urine biomarkers of biomedical responses to extrinsic stress, as well as subjective symptoms were longitudinally observed for up to 10 years in Japanese copier-industry workers responsible for the manufacturing, maintenance or recycling of powdered toner or toner-using machines. A total of 694 subjects who did not change their work category during the follow-up and were free from chronic respiratory diseases at the baseline survey provided reliable results on at least 3 survey occasions during 3 years or more of follow-up.

**Results:** Typical fibrosis findings associated with pneumoconiosis was not observed on chest radiograms. No significant differences associated with toner exposure were noted in the frequency of new incidence of either non-specific findings on chest radiogram or serum fibrosis biomarkers (KL6 and SPD). However the exposed subjects tended to show increases in the frequency of respiratory symptoms and reduced spirometry results during the follow-up

1  
2  
3  
4 compared with the control group, although significant differences were only seen in chronic  
5  
6 cough.  
7

8  
9 **Conclusions:** Under the current reasonably controlled work environmental conditions, lung  
10  
11 fibrotic changes caused by inhaled dust exposure, including powdered toner, appear to be  
12  
13 relatively uncommon; however, nonspecific temporal irritation causing subjective symptoms  
14  
15 and inflammatory responses might exist.  
16  
17  
18  
19  
20  
21  
22

23 Key words: Dust, Longitudinal studies, Respiratory, Epidemiology  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- An occupational cohort of workers in business machine industry exposed to printing toner dust in various types of work was followed for up to 10 years regarding their respiratory health status on an annual basis, mainly focusing on lung fibrotic changes.
- The incidence of newly emerging lung fibrotic changes was compared between the exposed workers and the non-exposed controls using wide-range health outcomes including chest X-ray findings, lung function results, and serum and urine biomarkers, as well as subjective symptoms.
- The total dust exposure during toner handling was measured in a representative sample of workers, but the fraction of toner particles in the whole dust exposure cannot be estimated accurately.
- Conventional chest radiography was utilized to evaluate lung fibrotic changes in an epidemiological research setting; however, computed tomography (CT) might have been more sensitive to early minimal fibrotic changes.
- Healthy worker bias might exist because some portion of the cohort ceased participation during the follow-up due to resigning, retiring, or transferring, although no toner-related health problems, such as lung fibrosis, were reported among these subjects.

## Introduction

Possible harmful effects of inhaled photocopier toner dust have been a matter of concern since the publication of several case reports suggesting the existence of toner-related pulmonary disorders [1][2][3]. However, little evidence is available regarding the potential for toner dust inhalation in occupational and general home environments where photocopier machines and laser printing devices are in use.

We reported the results of a cross-sectional study of toner-handling workers engaged in several types of toner exposure work [4]. Although the results suggested the limited possibility of adverse effects due to toner dust inhalation, it was also suggested that a study with longitudinal design would be useful for a more detailed examination of the hypothesized association between toner dust exposure and adverse health effects under current actual work conditions.

We therefore conducted a longitudinal study of toner-handling workers for 10 years in a business machine-producing company and affiliated companies involved in maintaining and recycling these machines in order to obtain longitudinal evidence to determine a possible health risk associated with a practical level of toner dust exposure under current actual work conditions, with particular focus on chronic fibrotic changes in the lungs.

This is the first report of this study and mainly presents the results of analyses of the

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

possible chronic health effects, including lung fibrotic changes as the principal research target, associated with toner dust exposure under current actual work conditions based on longitudinally observed health data.

For peer review only

## Methods

### *Subjects*

The subjects were employees of seven branches of a group of companies that produced, maintained, and recycled photocopiers, laser printers, and related products for printing with the use of powdered toner. We identified four categories of toner-handling work among the subjects. Toner production (TPD) represents work associated with any process in the course to producing powdered toner, such as mixing and molding raw materials, crushing toner mass, and filling and packing the products. Designing and development of machines (DDM) represents work associated with developing new models of toner-using business machines, in which various types of toner-handling procedures are involved. Maintenance (MTN) represents the work associated with maintaining photocopiers and laser printers in users' offices and homes. Recycling (RCL) represents work associated with processing recycled toner cartridges. The air environment was generally well-maintained using local ventilation instruments according to the regulations in Japan. The workers were therefore encouraged to wear respiratory protection masks in only limited situations where heavy exposure might occur, such as when cleaning the mixing tanks or performing maintenance on/repairing equipment.

The survey on the health status of the subjects started in the fall of 2003 and was



1  
2  
3  
4 repeated until 2013 basically on an annual basis in the same manner as the first one in 2003.  
5  
6 Throughout the entire study period, a total of 1176 toner handling workers (587 for TPD, 207  
7  
8 for DDM, 346 for MTN, and 36 for RCL) participated in at least one of these surveys.  
9  
10 However, some participants ceased participation during an early stage of the study for various  
11  
12 reasons other than toner-related health problems (e.g. resigning, retiring, or transferring), and  
13  
14 others started participating in a later stage of the study. Therefore, we defined the subjects  
15  
16 with a sufficient follow-up duration for a longitudinal data analysis in this paper as those who  
17  
18 started participating by the spring of 2005 and were followed-up for three years or more with  
19  
20 at least three surveys throughout the entire study period. In addition, subjects were those who  
21  
22 had not changed their work category (concerning the presence or absence of toner handling)  
23  
24 during their follow-up. The flowchart in Fig. 1 shows the number of participants included in  
25  
26 or excluded from the analysis based on the above-mentioned criteria.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 The number of toner workers who met the above criteria was 489. As a reference  
38  
39 population for comparison with these toner-handling workers, an additional 309 control  
40  
41 subjects who had never participated in any types of toner-handling work described above also  
42  
43 participated in this study by the spring of 2005. Among them, the 221 who met the same  
44  
45 criteria as exposed workers stated above were analyzed. Control subjects were recruited at  
46  
47 each participating branch and amounted to roughly half the number of toner-handling  
48  
49 workers. The control subjects basically worked in different buildings from the ones where the  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 exposed workers were engaged in toner-handling work. While the control subjects  
5  
6 occasionally happened to enter the factory area, such accidental exposure was quite limited.  
7  
8  
9

### 10 11 12 *Health status indices*

13  
14  
15 Subjects' health status was evaluated on an annual basis from various health-related aspects  
16  
17 using physiological, biochemical, and radiographic examination tools as well as via the  
18  
19 assessment of subjective symptoms and clinical signs. This evaluation focused mainly on  
20  
21 chronic respiratory deterioration, including pulmonary fibrotic conditions, and biological  
22  
23 responses to inhaled potentially harmful substances. Standardized methods were utilized for  
24  
25 health status measurement to keep the measurement bias as small as possible. The biomedical  
26  
27 indices examined in this study are described below.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 41 42 *Chest X-ray findings*

43  
44 Chest radiography was carried out to obtain a standardized anterior-posterior X-ray film by  
45  
46 using prescribed standard procedures to detect mineral-dust pneumoconiosis in Japan [5].  
47  
48 Each X-ray film was read by one of three readers with sufficient experience in the  
49  
50 radiographic diagnosis of pneumoconiosis while referencing the standard films for the  
51  
52 diagnosis [6]. The readers were privy to no information regarding the exposure status of the  
53  
54 subjects. The severity of fibrotic findings in the lung fields was classified into 12 grades,  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 from 0/- to 3/+, according to the distribution and density of the small opacities. This  
5  
6 classification was compatible with that of the International Labor Organization (ILO) [7].  
7  
8  
9 However, we noted none of the fibrotic findings typically observed in mineral dust  
10  
11 pneumoconiosis cases with 1/1 or a more severe grade profusion during early surveys.  
12  
13  
14 Therefore, we additionally recorded mild, non-specific findings, such as sparse irregular  
15  
16 opacity, unclear interstitial shadow, or disrupted vascular shadow in radiographs. These  
17  
18 findings were not only potentially related to early effects of toner toxicity but also might be  
19  
20 caused by acute or sub-acute non-specific irritation or infection, which might be reversible.  
21  
22  
23  
24  
25  
26  
27  
28

### 29 *Questionnaire survey*

30  
31 Detailed information regarding respiratory symptoms, allergic symptoms, past and present  
32  
33 medical history, and lifetime smoking history was obtained using a translated version of a  
34  
35 self-administered questionnaire standardized by the American Thoracic Society  
36  
37 (ATS-DLD-78A) [8], with slight modification and several additional questions on allergies of  
38  
39 the eye, nose, and skin. The responses were certified by several trained interviewers, and  
40  
41 supplemental interviews were held when necessary. Subjects were considered to have a  
42  
43 symptom when they gave an affirmative response to questions about the specific symptom.  
44  
45  
46  
47  
48  
49  
50  
51 The lifetime work history was also confirmed during this interview.  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Spirometry*

Subjects were asked to repeat the forced expiratory maneuver up to a maximum of five times in the standing position in order to obtain acceptable and reproducible spirometry results. The mechanical specifications of the spirometer used (DISCOM-21FX2; CHEST Co. Ltd., Tokyo, Japan) met the standards stipulated by ATS [9]. Routine BTPS correction and back-extrapolation were carried out. The calibration of the spirometer, spirometry measurements, and evaluation of the results were based on prescribed procedures described in detail elsewhere [10].

The percent predicted values standardized on sex, age, and height were calculated for forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and FEV1/FVC in each subject based on the prediction equations published by the Japanese Respiratory Society [11]. The values of FVC, FEV1, and FEV1/FVC were defined as reduced when they were smaller than the lower value of the confidence interval of the authorized reference equations described above. All figures were calculated from the best maneuver yielding the largest sum of FVC and FEV1 for each subject [12].

For the analysis of the longitudinal changes in spirometry indices, we calculated the height-squared proportional values of FVC ( $FVC/HT^2$ ) and FEV1 ( $FEV1/HT^2$ ) to adjust for differences in the body size. The annual decline in  $FVC/HT^2$  and  $FEV1/HT^2$  were calculated for each subject as a regression coefficient using a simple linear regression equation of those

1  
2  
3  
4 values against age during the follow-up period.  
5  
6  
7

8  
9 *Serum and urine biomarkers*  
10

11  
12 Peripheral venous blood and urine (10 and 20 ml, respectively) were obtained from each  
13  
14 subject at the time of every survey. Serum was immediately separated from whole blood  
15  
16 sample using a routine procedure. Then, serum and urine samples were deeply frozen at  
17  
18 -80 °C until analyses were carried out.  
19  
20  
21  
22

23  
24 As the indices of biological responses to inhaled extrinsic irritants like toner particles,  
25  
26 we employed the following biomarkers: highly sensitive C-reactive protein (CRP),  
27  
28 non-specific immunoglobulin E (IgE), sialylated carbohydrate antigen KL-6 (KL6), and lung  
29  
30 surfactant protein D (SPD) in serum, and 8-hydroxy deoxy guanosine (8OHdG) in urine. In  
31  
32 Japan, serum CRP, IgE, KL6, and SPD levels are routine clinical laboratory test items  
33  
34 assessed in common medical practice. The analyses of those results were therefore carried out  
35  
36 according to the appropriate Standard Operation Procedures (SOP) in SRL Inc., Tokyo.,  
37  
38 Japan which has been providing high quality testing under the certification of the Japan  
39  
40 Accreditation Board, a public service juridical foundation for ensuring the reliability of  
41  
42 clinical laboratory testing in Japan.  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 Urine 8OHdG was measured using an ELISA kit (New 8OHdG Check ELISA Kit;  
53  
54 Japan Institute for the Control of Aging) and was adjusted for urine condensation using the  
55  
56

1  
2  
3  
4 urine creatinine concentration as the denominator.  
5

6 The result of the measurement of each index was judged to be out of the normal range  
7  
8 when the value exceeded the following figures: 1500 ng/ml for CRP, 173 IU/ml for IgE,  
9  
10 500 U/ml for KL6, 110 ng/ml for SPD, and 20 ng/mg creatinine for 8OHdG.  
11  
12  
13  
14

### 15 16 17 18 *Exposure assessment*

19 We directly measured the personal exposure levels in individual toner-handling workers.  
20  
21

22 The average diameter of the toner particles contained in the products handled by the workers  
23  
24 in this study was about 10  $\mu\text{m}$ . Workers were asked to wear a portable personal dust sampler  
25  
26 (NWPS-254 sampler with a T60A20 sampling filter, SIBATA SCIENTIFIC TECHNOLOGY  
27  
28 Ltd., Tokyo, Japan) that continuously sampled the air in the workplace environment at 2.5  
29  
30 L/min air flow driven by a MP-2N or MP-3 $\Sigma$  pump (SIBATA SCIENTIFIC TECHNOLOGY  
31  
32 Ltd., Tokyo, Japan). The sampling head was located around the neck of each subject to  
33  
34 collect particles suspended in the air throughout a given period of toner-related work. The  
35  
36 respirable fraction was separated using filters designed to cut 50% of 4- $\mu\text{m}$ -diameter particles.  
37  
38 The concentration of total and respirable dust exposed to the workers was calculated as a  
39  
40 time-weighted average value for 8 h (TWA-8h) based on the amount of dust collected on the  
41  
42 filter and the total volume of air inspired by the sampling pump. Measurements were  
43  
44 conducted basically twice a year for at least 5 workers in each toner-handling procedure,  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 yielding a total of 2042 measurements (1751 for TPD, 81 for DDM, 88 for MTN, and 122 for  
5  
6 RCL) throughout the study period. Those values obtained were evaluated with reference to  
7  
8 the recommendations by the Japan Association of Industrial Health (JAIH) [13]. We also  
9  
10 analyzed several chemical components that were generated when the toner was heated at a  
11  
12 temperature of around 180 degrees centigrade as representative components of powdered  
13  
14 toner using gas chromatography and mass spectrometry (GC-MS) in order to estimate the  
15  
16 toner exposure separately from other types of dusts suspended in the air. However, we were  
17  
18 unable to obtain reliable estimates of the amount of toner dust fraction in the whole dust  
19  
20 cluster collected on the sampling filter, mainly because of large variability of the values  
21  
22 depending on the types of toner handled.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 *Analyses*

- 36  
37 • Cross-sectional evaluation of baseline data

38  
39 For each subject, we considered the results obtained in the first year of participation as the  
40  
41 baseline data, indicating the condition at the beginning of the longitudinal observation of this  
42  
43 study. The relative frequency of subjects with positive results was calculated for each  
44  
45 health-related item described above (prevalence) and compared statistically between the  
46  
47 exposed subjects as a whole and the control subjects. The significance of differences in the  
48  
49 prevalence between the exposed subjects and controls was assessed using a chi-squared test  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 and Fisher's exact test as appropriate. A multiple logistic regression analysis was used to  
5  
6 obtain the OR estimates adjusted for possible confounding factors.  
7  
8  
9

- 10  
11  
12 • Longitudinal evaluation of chronic fibrotic findings  
13

14  
15 For the longitudinal analysis, we mainly focused on the results associated with chronic  
16  
17 respiratory toxicity, including the fibrotic potential of toner dust inhalation exposure. To this  
18  
19 end, we analyzed the changes in chest radiographic findings during the follow-up period. We  
20  
21 also used three pulmonary function indices (FVC, FEV1, and FEV1/FVC) and two serum  
22  
23 biomarkers (KL6 and SPD, both of which are recognized as useful markers of active-phase  
24  
25 fibrotic conditions in the lungs) [14]. In addition, we selected three chronic respiratory  
26  
27 symptoms associated with chronic respiratory diseases, such as fibrotic lung changes, namely  
28  
29 chronic cough, chronic phlegm, and breathlessness. Chronic cough, as well as chronic  
30  
31 phlegm, was considered to be present when the symptom existed for three months or more in  
32  
33 a year. Breathlessness was considered to be present when a subject walked slower than their  
34  
35 counterparts of the same age on level ground.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 In the longitudinal data analysis, we evaluated the frequency of abnormalities that  
47  
48 newly emerged during the follow-up observation (incidence). Abnormalities were considered  
49  
50 to be present when the respiratory symptom or the X-ray findings were newly noted or when  
51  
52 the pulmonary function or biomarker values exceeded the normal range during follow-up.  
53  
54  
55  
56



1  
2  
3  
4 Therefore, those subjects who already had abnormalities at their baseline survey were  
5  
6 excluded from the longitudinal data analysis. The incidence was compared between the  
7  
8 exposed workers as a whole and the control subjects, as well as by the work categories. In a  
9  
10 similar manner to the cross-sectional analyses, the incidence was compared using a  
11  
12 chi-squared test or Fisher's exact test as appropriate, and the OR estimates adjusted for  
13  
14 confounders were calculated using a multiple logistic regression analysis.  
15  
16  
17  
18  
19  
20  
21  
22

### 23 *Statistical analyses*

24  
25  
26 For comparisons by exposure categories, the chi-squared test and Fisher's exact test as well as  
27  
28 a multiple logistic regression analysis were performed for categorical variables, and a simple  
29  
30 *t*-test and an analysis of covariance were performed for numeric variables, with the alpha  
31  
32 error level set at 0.05. All statistical tests and estimations were carried out using the SAS  
33  
34 statistical package on a personal computer (PC-SAS Version 9.2; SAS Institute Inc., Cary, NC,  
35  
36 USA).  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 *Ethical considerations*

47  
48 The objectives and outline of the study were explained to the subjects at the beginning of the  
49  
50 study, and written informed consent was obtained from each participant. All information  
51  
52 obtained in this study was handled in accordance with the guidelines for epidemiological  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 studies authorized in Japan [15]. This study was conducted under the approval of the  
5  
6 Institutional Review Board on Medical Ethics of Showa University School of Medicine  
7  
8  
9 (Authorization No. 201).  
10

11  
12  
13  
14  
15 *Patient involvement*  
16

17 Patients were not involved in this study.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

As stated earlier, we selected 710 workers (489 exposed and 221 controls) as the subjects for this longitudinal data analysis. Among them, 16 subjects reported that they had suffered from chronic respiratory diseases prior to the beginning of this study (chronic obstructive pulmonary disease and/or pulmonary tuberculosis). These subjects were therefore excluded, and the remaining 694 subjects were ultimately analyzed (Fig. 1). The average number of surveys in which those subjects participated was 6.8, and the average follow-up duration (elapsed time from the first observation to the final one) was 7.4 years. No significant difference was observed in those average values between the exposed and control groups.

Several background characteristics at the baseline point, as well as the results of personal exposure measurements during the entire study period as the 10th and 90th percentile values of the TWA-8h concentration, were compared among the exposure categories in Table 1. The male to female ratio was comparable between the exposed and control groups. However, the absolute number of female subjects was quite small compared to males, with only 28 women analyzed. Significant differences were observed between the exposed and control groups in mean age and smoking habit classification at the baseline survey, with the exposed group being younger and more likely to smoke than the controls. Seventy-six of 360 current smokers at baseline quit smoking during their follow-up period,

1  
2  
3  
4 whereas only 1 out of 220 never smokers at the point of baseline started smoking during the  
5  
6 follow-up. As for body size, the mean values of standing height and body mass index (BMI)  
7  
8 were comparable between the exposed and control groups.  
9  
10

11  
12 The TPD and RCL workers tended to show higher percentile values both in the total  
13  
14 and respirable TWA-8h than the DDM and MTN workers. As suggested by those summary  
15  
16 percentile values, the individual TWA-8h values distributed across a rather wide range, and  
17  
18 some of them exceeded the permissible limit recommended by JAIH (4 mg/m<sup>3</sup> as total and 1  
19  
20 mg/m<sup>3</sup> as respirable carbon black dust, and 8 mg/m<sup>3</sup> as total and 2 mg/m<sup>3</sup> as respirable  
21  
22 general dust) [13]. However, the overall median TWA-8h values of both total and respirable  
23  
24 dust were well below the JAIH recommendations, even among the TPD and RCL workers.  
25  
26 Fig. 2 shows the time-dependent change in those summary statistics of personal exposure  
27  
28 measurement during the study period. No marked trends were observed in the percentile  
29  
30 values during the 10-year follow-up, suggesting that the work environment was relatively  
31  
32 stable throughout the study period in terms of dust exposure to the workers as a whole.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 Table 2 summarizes the prevalence of the biomedical indices studied at the baseline  
44  
45 survey according to the exposure categories. The odds ratios (ORs) and their 95% confidence  
46  
47 intervals (CIs) of the exposed to the control group are also shown after adjustment for  
48  
49 possible confounding variables. The exposed group tended to show higher prevalence in  
50  
51 respiratory symptom indices, although significant differences were observed only in chronic  
52  
53  
54  
55  
56

1  
2  
3  
4 phlegm and wheeze grade 2. The prevalence values for CRP and IgE abnormalities were also  
5  
6 significantly larger in the exposed group than in the control group, although the results of  
7  
8 KL6 and SPD were comparable between the two groups. The difference in CRP remained  
9  
10 significant even after adjustment for BMI, a well-known contributor to the serum CRP level.  
11  
12  
13  
14 Only a small number of subjects demonstrated values outside of the reference ranges of FVC,  
15  
16 FEV1 or FEV1/FVC, and the prevalence showed values ranging from 2 to 6 %. There were  
17  
18 no cases of clear pneumoconiosis with 1/1 or a more severe grade on baseline chest X-ray  
19  
20 films of the subjects analyzed, although non-specific findings were noted in 3.4% of the  
21  
22 exposed and 1.8% of the control subjects at baseline. No significant difference between the  
23  
24 two groups was noted in the prevalence at baseline of either the pulmonary function or chest  
25  
26 X-ray indices.  
27  
28  
29  
30  
31  
32  
33

34  
35 Table 3 compares the frequency of newly emerging abnormalities observed during the  
36  
37 follow-up period between the exposed and control groups for selected biomedical indices in  
38  
39 order to examine the degree of chronic respiratory deterioration, including lung fibrotic  
40  
41 changes. This table also includes the results of comparisons according to work categories,  
42  
43 although no RCL workers were included in this analysis because the number of such workers  
44  
45 was too small; namely, only seven workers. After carefully evaluating the chest X-ray films  
46  
47 accumulated during the follow-up period, we observed no cases with 1/1 or a more severe  
48  
49 grade of pneumoconiosis. In addition, the incidence of non-specific findings during the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 follow-up was comparable between the exposed and control groups. Furthermore, two  
5  
6 clinically useful biomarkers of lung fibrosis (KL6 and SPD) showed rather low incidence  
7  
8 values for newly emerging abnormalities, which were comparable between the exposed and  
9  
10 control groups. However, regarding symptoms and the pulmonary function, the exposed  
11  
12 group tended to have a higher incidence of abnormalities more frequently than the control  
13  
14 group. The ORs estimated by logistic regression analyses mostly exceeded 1.5, and after  
15  
16 adjustment for age and smoking status during the follow-up period, chronic cough emerged  
17  
18 significantly more frequently in the exposed subjects than in the control group. In the  
19  
20 analyses according to work categories, an increase in the OR value of chronic cough was  
21  
22 observed in all exposed work categories that were analyzed, and reaching a statistically  
23  
24 significant level in DDM and MTN workers. The TPD, the highest exposure category, tended  
25  
26 to show a more consistent elevation of OR values versus the controls than other work  
27  
28 categories.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Table 4 shows the comparison of  $FVC/HT^2$  and  $FEV1/HT^2$  decline during the  
41  
42 follow-up period among the exposure categories. Comparable values were obtained for both  
43  
44 indices between the exposed as a whole and the control groups. After adjustment for the  
45  
46 significant contribution of age, toner exposure was not a significant factor influencing the  
47  
48 decline in the pulmonary function.  
49  
50  
51  
52

53  
54 Table 5 summarizes the significant independent contribution of confounding factors in  
55  
56

1  
2  
3  
4 the multivariate analyses described in Tables 2 and 3 as estimated ORs for the health-related  
5  
6 outcomes. Only statistically significant results are presented with their 95% CIs. Smoking  
7  
8 was considered to increase the incidence of chronic phlegm, SPD abnormality, and reduced  
9  
10 FVC and FEV1 during follow-up, as well as the prevalence of many symptoms and a reduced  
11  
12 pulmonary function at baseline. Similar increases in ORs with age were also observed for the  
13  
14 incidence during the follow-up and the prevalence at baseline of some of the examined  
15  
16 indices. A clear independent association between serum CRP abnormalities and obesity was  
17  
18 also observed.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

Photocopiers and laser printers using powdered toner are widely used in offices and homes, but the powdered toner for printing and emissions from these machines may become air pollutants in office and home environments [16][17]. McGarry et al. reported the condition of particulate air pollution resulting from the use of laser printers in several actual office environments [18]. As several case reports have suggested the existence of chronic pulmonary disorders possibly associated with inhaled toner dust [1][2][3], many aspects of toner-related health effects have been reported. Khatri et al. [19] conducted a human volunteer exposure study in an actual current office environment and found that several biomarkers, including 8OHdG as a marker of oxidative stress [20], changed in relation with the particulate air pollutants emitted by photocopiers and laser printers, although those changes were acute or sub-acute and not chronic in nature. Elango et al. [21] reported the result of a cross-sectional study on photocopier center workers in India, showing the significant elevation of serum inflammatory biomarkers among the exposed workers compared with the controls. Kasi et al. [22] suggested possible genotoxicity associated with photocopier-related exposure in a survey of photocopier operators and maintenance workers. Yanagi et al. [23] found no marked difference in the pulmonary function due to toner-related work in their cross-sectional analysis of workers at a business equipment manufacturer. In



1  
2  
3  
4 their critical review, Pirela et al. [24] stated that particulate matter, including nanoparticles  
5  
6 emitted from photocopiers and laser printers during operations, could exert biological effects  
7  
8 on the respiratory system, such as oxidative stress and inflammatory responses.  
9  
10

11  
12 Compared with human volunteer or cross-sectional epidemiological studies, the  
13  
14 evidence obtained by longitudinal epidemiological studies is quite limited, but longitudinal  
15  
16 study results are needed to fully examine the health impact of particulate air pollutants  
17  
18 associated with office machines, as far as chronic health effects are concerned. In a cohort  
19  
20 study on toner and photocopier manufacturing workers conducted over four years, no  
21  
22 evidence was obtained regarding the adverse effects on the pulmonary function or chest  
23  
24 X-ray findings associated with toner-handling work [25][26], although an increased  
25  
26 prevalence of breathlessness was observed in association with toner-handling work [27].  
27  
28  
29 However, those studies did not evaluate the incidence of abnormalities based on  
30  
31 longitudinally observed data. Therefore, we conducted a longitudinal study to further  
32  
33 evaluate the possible health effects of toner dust exposure as a subsequent study of our  
34  
35 cross-sectional one mentioned above [4] with a focus mainly on the chronic respiratory  
36  
37 effects, such as lung fibrotic changes. To determine the actual risk in the current real-world  
38  
39 environment, we studied an actual working population. Personal exposure measurement  
40  
41 results showed that the current level of exposure to total and respirable dust in toner-handling  
42  
43 workers was on average well below the permissible exposure levels of general mineral dust  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 and carbon black dust recommended by JAIH [13], even among TPD and RCL workers, in  
5  
6 whom relatively high exposure was observed. We also used several biomedical indices to  
7  
8 detect possible harmful effects on the respiratory system: namely imaging findings by chest  
9  
10 X-ray, KL6 and SPD levels in serum as clinically utilized biomarkers on lung fibrosis,  
11  
12 spirometry results to evaluate the lung functional status, and subjective symptoms obtained  
13  
14 through standardized methods.  
15  
16  
17  
18

19  
20 In a cross-sectional analysis of the baseline results, the exposed group tended to have  
21  
22 subjective symptoms more frequently than in the control group, and similar group differences  
23  
24 were observed in the frequency of abnormal values in the majority of the biomedical indices  
25  
26 examined. In addition, the difference between the two groups reached a statistically  
27  
28 significant level in several items, even after controlling for confounders. This tendency was  
29  
30 basically consistent with what we had previously reported, with exposed workers  
31  
32 complaining of symptoms more frequently than control workers despite having a comparable  
33  
34 frequency of pulmonary function and chest radiography abnormalities. Although the presence  
35  
36 of consistent difference between the groups might suggest the existence of certain subclinical  
37  
38 changes, the cross-sectional evaluation at the baseline might have been influenced by a  
39  
40 number of factors prior to the start of this study. Therefore, newly emerging abnormalities  
41  
42 during follow-up should be examined in subjects without any abnormalities at the baseline  
43  
44 observation, as far as the chronic health effects are concerned. One interesting finding of the  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 cross-sectional analysis was the higher prevalence of CRP abnormalities, a sensitive marker  
5  
6 of acute inflammatory status in the body, among the exposed subjects compared with control  
7  
8 subjects. It seems unlikely that the elevated CRP values were significantly influenced by  
9  
10 events in the past due to its nature as an acute inflammatory biomarker. In addition, the  
11  
12 difference seemed to be independent of inflammatory conditions caused by obesity or  
13  
14 smoking, as both were used as adjustment factors in the logistic regression model. These  
15  
16 findings suggest that acute inflammatory conditions might be associated with current toner  
17  
18 exposure. At the same time, an increase in the serum IgE level was also frequently found in  
19  
20 the exposed subjects. In Japan, an allergy to cedar pollen is commonly observed every spring,  
21  
22 so cedar pollinosis may be related to the findings for CRP and IgE. However, as there are  
23  
24 multiple factors affecting the CRP [28] as well as the IgE levels, we were unable to specify  
25  
26 the reason for that group difference.  
27  
28  
29  
30  
31  
32  
33  
34  
35

36  
37 In the longitudinal analyses of biomedical indices, we evaluated the frequency of a  
38  
39 newly emerging abnormality during the follow-up period by excluding the subjects from the  
40  
41 analysis if they already had the finding at baseline. Among the indices associated with lung  
42  
43 fibrotic changes, we found closely similar results between the exposed and control groups  
44  
45 regarding the new incidence of chest radiographic findings and serum biomarker  
46  
47 abnormalities. These results suggest that the fibrogenic potential of dust exposure associated  
48  
49 with toner-handling work seems to be minimal, if any at all, as far as the current working  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 environment is concerned.  
5

6  
7 In contrast, the estimated ORs for FEV1/FVC abnormality adjusted for confounders  
8  
9 showed a relatively a large value exceeding 1.5, although the increase was not statistically  
10  
11 significant. A statistically significant increase in the OR of TPD versus the controls was  
12  
13 observed in FVC and FEV1 abnormalities. However, the overall differences in the incidence  
14  
15 of reduced FVC and FEV1 were relatively small between the exposed subjects and control  
16  
17 subjects. Furthermore, the annual declines in the  $FVC/HT^2$  and  $FEV1/HT^2$  of the exposed  
18  
19 subjects during the follow-up period were comparable to those of the control subjects after  
20  
21 controlling for the age and smoking status during the follow-up. Thus, it seems difficult to  
22  
23 attribute certain biological or medical reasons to the moderate, but a insignificant elevation in  
24  
25 ORs that was seen regarding the pulmonary function index abnormality. Some fluctuation  
26  
27 around normal ranges might be partially responsible for the observed elevation in OR values.  
28  
29 In the case of chronic cough, the exposed group showed a larger incidence than the control  
30  
31 group. This finding was not associated with the findings for chronic phlegm, which showed a  
32  
33 comparable incidence after adjusting for the significant contribution of smoking. This  
34  
35 suggests that the significant increase in the rate of chronic cough cannot be attributed to  
36  
37 mucus hypersecretion. Given the findings at baseline mentioned earlier, it might be possible  
38  
39 to hypothesize that non-specific irritation leading to subjective symptoms, fluctuation in the  
40  
41 pulmonary function, and inflammatory response were caused to some extent by exposure  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 associated with toner-handling work.  
5

6  
7 However, of note: in all indices selected for the longitudinal incidence analyses, the  
8  
9 OR value adjusted for confounders exceeded the unit value without exception, suggesting  
10  
11 mostly non-significant but consistent elevation of the incidence in the exposed workers.  
12  
13 Therefore, further epidemiological studies are needed in order to identify mild and  
14  
15 nonspecific effects in a large-scale sample with sufficient statistical power. In this context, a  
16  
17 similar tendency toward a consistent OR elevation was observed in TPD work, which was  
18  
19 associated with the greatest exposure of total and respirable dust in the personal exposure  
20  
21 measurement. However, it was difficult to make any conclusions regarding this consistency in  
22  
23 relation to the toner exposure levels, because no information was obtained regarding the exact  
24  
25 percentage of toner included in the total dust sampled. The toner particle exposure should be  
26  
27 measured separately from other substances in future studies.  
28  
29  
30  
31  
32  
33  
34  
35

36  
37 Several limitations associated with the present study warrant mention. First, the  
38  
39 number of subjects of this study (694 in total) might be insufficient to detect minimal and  
40  
41 subclinical health deteriorations, although this study seems to have reasonably sufficient  
42  
43 power to detect at least well-established health risks, such as aging, smoking, and obesity. A  
44  
45 meta-analysis of the studies with a common methodological basis will be useful for detecting  
46  
47 minimal effects of toner dust. Second, we obtained measurements on personal exposure  
48  
49 concentration for each work category as an exposure assessment. However, the results  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 showed large variability. In addition, we were unable to obtain reliable data on the relative  
5  
6 content of toner as a fraction of the whole dust sample. We therefore cannot reliably estimate  
7  
8 the amount of personal exposure to toner dust for each individual subject. An analysis of the  
9  
10 dose-response relationship will require a more precise exposure assessment for toner dust.  
11  
12  
13  
14 Third, we simply utilized conventional chest radiography and did not use computed  
15  
16 tomography (CT) to evaluate lung fibrotic changes, because we should minimize the amount  
17  
18 of X-rays that the participants were exposed to in an epidemiological research setting. We  
19  
20 were therefore unable to distinguish the non-specific findings in cases where  
21  
22 extremely-early-phase of toner-related changes might have been included. Advanced  
23  
24 radiography techniques will be useful for the more precise evaluation of lung fibrotic  
25  
26 deterioration caused by toner dust inhalation.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conclusion

Under the current reasonably controlled work environmental conditions, lung fibrotic changes caused by inhaled dust exposure, including powdered toner, appear to be relatively uncommon; however, nonspecific temporal irritation causing subjective symptoms and inflammatory responses might exist. Further epidemiological research will be useful for clarifying the possible health effects of toner dust exposure fully, especially the minimal and non-specific health changes in a study setting with a sufficient sample size to detect these changes.

## Acknowledgments

The authors thank all the subjects, investigators and survey staff who participated in this longitudinal study over 10 years.

## Footnotes

**Contributors:** TN designed the study; TN and YY executed the data collection in annual surveys; YY, TY, SO and DN contributed to the data preparation and analyses; TN wrote the initial manuscript. All of the authors contributed to the revision of the manuscript and approved the final form of the manuscript for submission.

**Funding:** This study was funded in part by Ricoh Co., Ltd., a photocopier industry company in Japan.

**Competing interest:** The authors report no conflicts of interest for the submitted work.

**Data sharing statement:** No additional data available.



## References

- [1] Gallardo M, Romero P, Sanchez-Quevedo MC, Lopez-Caballero JJ. Siderosilicosis due to photocopier toner dust. *Lancet* 1994 Aug 6;344(8919):412-3.
- [2] Armbruster C, Dekan G, Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust. *Lancet* 1996 Sep 7;348(9028):690.
- [3] Wieriks J. Photocopier toner dust and lung disease. *Lancet* 1996 Nov 30;348(9040):1518-9.
- [4] Nakadate T, Yamano Y, Adachi C, Kikuchi Y, Nishiwaki Y, Nohara M, Satoh T, Omae K. A cross-sectional study of the respiratory health of workers handling printing toner dust. *Occup Env Med* 2006;63:244-9.
- [5] Department of Health and Safety. Ministry of Labour, Japan. *Jinpai Shinsa handbook* (Pneumoconiosis examination handbook). Tokyo: Japan Safety and Health Association, 1978. (In Japanese)
- [6] Ministry of Labour, Japan. *Jinpai Hyoujun x-ray films* (Standard x-ray films for diagnosis of pneumoconiosis). Tokyo: Japan Safety and Health Association, 1982. (In Japanese)
- [7] International Labour Organization. *International Classification of Radiographs of Pneumoconioses* (Revised, 2000). 2002.
- [8] Ferris BG. Epidemiology standardization project. *Am Rev Respir Dis* 1978;118(6, 2 of 2

1  
2  
3  
4 parts):57-62.  
5

6 [9] American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir  
7  
8 Crit Care Med 1995;152:1107-36.  
9

10  
11 [10] Nakadate T, Aizawa Y, Yagami T, Zheng YQ, Kotani M. Change in obstructive  
12  
13 pulmonary function as a result of cumulative exposure to welding fumes as determined by  
14  
15 magnetopneumography in Japanese arc welders. Occup Environ Med 1998;55:673-7.  
16  
17

18  
19 [11] Kubota M, Kobayashi H, Quanjer PH, Omori H, Tatsumi K, Kanazawa M; Clinical  
20  
21 Pulmonary Functions Committee of the Japanese Respiratory Society. Reference values for  
22  
23 spirometry, including vital capacity, in Japanese adults calculated with the LMS method and  
24  
25 compared with previous values. Respir Investig. 2014 Jul;52(4):242-50).  
26  
27  
28

29  
30 [12] Nakadate T. Longitudinal observation of pulmonary function decline in male Japanese  
31  
32 workers: design, baseline results, and methodological considerations of handling pulmonary  
33  
34 function data. Ind Health 1998;36:305-11.  
35  
36  
37

38  
39 [13] Japan Association of Industrial Health. Recommendation on threshold limit values,  
40  
41 Japan (2016). Sangyo Eiseigaku Zasshi 2016;58(5):181-212. (In Japanese)  
42  
43  
44

45  
46 [14] Hermans C, Bernard A. Lung epithelium-specific proteins: characteristics and potential  
47  
48 applications as markers. Am J Respir Crit Care Med. 1999;159(2):646-78.  
49  
50

51  
52 [15] Ministry of Education, Culture, Sports, Science and Technology, and Ministry of Health,  
53  
54 Welfare, and Work, Japan. Ethical Guidelines for Epidemiological Studies. June 17, 2002.  
55  
56

1  
2  
3  
4 <http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/ekigaku/0504sisin.html> (in Japanese)

5  
6 [16] He C, Morawska L, Taplin L. Particle emission characteristics of office printers. *Environ*  
7  
8  
9 *Sci Technol* 2007;41(17):6039-45.

10  
11 [17] Tang T, Hurras J, Gminski R, Mersch-Sundermann V. Fine and ultrafine particles emitted  
12  
13  
14  
15 from laser printers as indoor air contaminants in German offices. *Environ Sci Pollut Res Int*  
16  
17  
18 2012;19(9):3840-9.

19  
20 [18] McGarry P, Morawska L, He C, Jayaratne R, Falk M, Tran Q, Wang H. Exposure to  
21  
22  
23  
24  
25 particles from laser printers operating within office workplaces. *Environ Sci Technol*. 2011  
26  
27 Aug 1;45(15):6444-52.

28  
29 [19] Khatri M, Bello D, Gaines P, Martin J, Pal AK, Gore R, Woskie S. Nanoparticles from  
30  
31  
32  
33  
34 photocopiers induce oxidative stress and upper respiratory tract inflammation in healthy  
35  
36  
37  
38  
39 volunteers. *Nanotoxicology* 2013;7(5):1014-27.

40  
41 [20] Irie M1, Tamae K, Iwamoto-Tanaka N, Kasai H. Occupational and lifestyle factors and  
42  
43  
44  
45 urinary 8-hydroxydeoxyguanosine. *Cancer Sci*. 2005 ;96(9):600-6.

46  
47 [21] Elango N, Kasi V, Vembhu B, Poornima JG. Chronic exposure to emissions from  
48  
49  
50  
51 photocopiers in copy shops causes oxidative stress and systematic inflammation among  
52  
53  
54  
55 photocopier operators in India. *Environ Health*. 2013;12(1):78.

56  
57 [22] Kasi V, Elango N, Ananth S, Vembhu B, Poornima JG. Occupational exposure to  
58  
59  
60 photocopiers and their toners cause genotoxicity. *Hum Exp Toxicol*. 2018;37(2):205-217.

- 1  
2  
3  
4 [23] Yanagi N, Kitamura H, Mizuno M, Hata K, Uchiyama T, Kuga H, Matsushita T, Kurosak  
5  
6 S, Uehara M, Ogami A, Higashi T. A 4-Year Follow-up Cohort Study of the Respiratory  
7  
8 Functions in Toner-handling Workers. *Saf Health Work*. 2014;5(4):222-6.  
9  
10  
11 [24] Pirela SV, Martin J, Bello D, Demokritou P. Nanoparticle exposures from nano-enabled  
12  
13 toner-based printing equipment and human health: state of science and future research needs.  
14  
15 *Crit Rev Toxicol*. 2017;47(8):678-704.  
16  
17  
18 [25] Kitamura H, Terunuma N, Kurosaki S, Hata K, Masuda M, Kochi T, Yanagi N, Murase T,  
19  
20  
21 Ogami A, Higashi T. A cohort study using pulmonary function tests and x-ray examination in  
22  
23 toner-handling workers: cross-sectional and longitudinal analyses from 2003 to 2008. *Hum*  
24  
25 *Exp Toxicol*. 2015;34(4):345-56.  
26  
27  
28 [26] Ikegami K1, Hasegawa M, Ando H, Hata K, Kitamura H, Ogami A, Higashi T. A cohort  
29  
30  
31 study of the acute and chronic respiratory effects of toner exposure among handlers: a  
32  
33  
34 longitudinal analyses from 2004 to 2013. *Ind Health*. 2016 ;54(5):448-459.  
35  
36  
37 [27] Kitamura H, Terunuma N, Kurosaki S, Hata K, Masuda M, Kochi T, Yanagi N, Murase ,  
38  
39  
40  
41 Ogami A, Higashi T. A cohort study on self-reported respiratory symptoms of toner-handling  
42  
43 workers: cross-sectional and longitudinal analysis from 2003 to 2008. *Biomed Res Int*.  
44  
45  
46 2014;2014:826757.  
47  
48  
49  
50 [28] Landry A, Docherty P, Ouellette S, Cartier LJ. Causes and outcomes of markedly  
51  
52  
53 elevated C-reactive protein levels. *Can Fam Physician*. 2017;63(6):e316-e323.  
54  
55  
56

1  
2  
3  
4  
5  
6 **Figure legends**  
7  
8  
9  
10

11 **Fig. 1 The number of subjects analyzed based on the inclusion criteria of this study**  
12  
13  
14

15  
16  
17  
18  
19  
20 **Fig. 2. The exposure levels of toner-handling workers by year of measurement estimated**  
21  
22 **by personal exposure measurements.** The values are presented as the median and the 10th  
23  
24 and 90th percentiles (%ile) for personal exposure measurement data.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Background characteristics of the subjects according to the exposure category.**

Characteristics	Category of exposure condition						<i>p</i> <sup>†</sup>
	Control	Exposed*					
		Total	TPD	DDM	MTN	RCL	
Number surveyed	217	477	175	145	150	7	
Sex (M/F)	205/12	461/16	167/8	141/4	149/1	4/3	0.18
Age (years)	39.1(8.2)	34.1(8.1)	32.9(10.3)	35.4(6.5)	34.2(6.3)	32.4(7.6)	<0.0001
Height (cm)	170.1(6.6)	170.3(6.4)	169.0(6.1)	171.3(6.4)	171.4(6.4)	161.5(6.8)	0.63
BMI (kg/m <sup>2</sup> )	23.0(3.1)	23.0(3.7)	23.2(4.6)	22.4(2.6)	23.4(3.2)	19.9(1.5)	0.999
Smoking habit <sup>‡</sup>							0.026
Never	70(32)	150(31)	38(22)	69(48)	38(25)	5(71)	
Former	47(22)	67(14)	17(10)	26(18)	24(16)	0	
Current	100(46)	260(55)	120(68)	50(34)	88(59)	2(29)	
Personal exposure (mg/m <sup>3</sup> )							-
Number of samples		2042	1751	81	88	122	
Total dust							

10 <sup>th</sup> % ile	0.08	0.09	0.04	0.07	0.51
Median	0.49	0.50	0.08	0.17	1.46
90 <sup>th</sup> % ile	2.38	2.14	0.38	0.80	5.60
Respirable dust					
10 <sup>th</sup> % ile	0.03	0.03	0.03	0.03	0.02
Median	0.05	0.09	0.03	0.03	0.04
90 <sup>th</sup> % ile	0.36	0.35	0.04	0.15	0.64

\* TPD: toner production, DDM: machine design and development, MTN: maintenance, RCL: recycling, BMI: body mass index

†Probability under the hypothesis that there are no differences between the control group and the exposed group as a whole.

‡Percentage of column total in parentheses.

Values are presented as the number of subjects for sex and smoking habit and the arithmetic mean (standard deviations) for age, height, and BMI at the baseline survey.

**Table 2. The comparison of the baseline status in select biomedical indices at the point of the first examination for each subject between the exposed subjects as a whole and the controls**

Biomedical indices	Univariate analysis			Multivariate analysis	
	Exposed	Controls	<i>p</i> *	OR <sup>†</sup>	95%CI <sup>†</sup>
Respiratory symptoms <sup>‡</sup>					
Cough #1 (7A)	19.4	14.8	0.14	1.35	(0.85-2.14)
Cough #2 (7B)	14.8	11.1	0.19	1.41	(0.84-2.37)
Chronic cough (7E)	5.5	4.2	0.46	1.6	(0.70-3.64)
Phlegm #1 (8A)	23.7	20.4	0.34	1.23	(0.81-1.87)
Phlegm #2 (8B)	13.5	10.7	0.29	1.45	(0.85-2.48)
Chronic phlegm (8E)	8.9	4.2	0.03	2.62	(1.20-5.70)
Exacerbation (9A)	10.5	7	0.14	1.56	(0.84-2.91)
Wheeze #1 (10A1)	9.5	5.6	0.09	1.51	(0.76-2.99)
Wheeze #2 <sup>§</sup> (10A2)	2.7	0	0.01	-	-
Chronic Wheeze (10A3)	0	0	-	-	-
Breathlessness #1 (13A)	9.7	11.6	0.45	1	(0.58-1.73)



Breathlessness #2 <sup>§</sup> (13B)	2.2	1.4	0.76	2.27	(0.58-8.89)
Breathlessness #3 <sup>§</sup> (13C)	0.4	0.9	0.59	0.96	(0.13-7.20)
Biomarker abnormality					
CRP	12.0	6.0	0.02	2.02	(1.05-3.88)
IgE	31.7	20.8	0.003	1.66	(1.12-2.48)
8OHdG <sup>§</sup>	1.1	1.8	0.47	0.68	(0.17-2.78)
KL6 <sup>§</sup>	0.4	0	1	-	-
SPD	3.2	3.4	0.89	0.91	(0.35-2.37)
Reduced pulmonary function					
FVC	6.5	6.0	0.76	1.00	(0.49-2.00)
FEV1	6.1	2.8	0.06	2.09	(0.83-5.27)
FEV1/FVC <sup>§</sup>	2.1	5.1	0.03	0.44	(0.18-1.09)
Chest X-ray findings					
Fibrotic change $\geq 1/1$	0	0	1	-	-
Non-specific findings	3.4	1.8	0.27	2.47	(0.78-7.81)

\* Probability under the hypothesis that there are no differences between the control group and exposed group as a whole examined by the chi-squared test or Fisher's exact probability method.

1  
2  
3  
4 † Odds ratio (OR) and its 95% confidence intervals (95% CI) of the exposed group to the  
5  
6 control group, regarding the positive findings at the baseline survey  
7

8  
9 ‡ The ATS-DLD-78A questionnaire code is shown in the parentheses  
10

11 § Fisher's exact probability method was applied.  
12

13  
14 # Grade of symptom severity: cough #1 and phlegm #1, usually having the symptom; cough  
15  
16 #2 and phlegm #2, 4 to 6 times a day on 4 or more days a week; wheeze #1, when having a  
17  
18 cold; wheeze #2, occasionally apart from cold; breathlessness #1, when hurrying on the level  
19  
20 or walking up a slight hill; breathlessness #2, having to walk slower than people your age on  
21  
22 the level; breathlessness #3, having to stop for breath when walking at your own pace.  
23  
24  
25  
26  
27

28  
29 The figures in the column of prevalence represent the proportion of subjects with symptoms  
30  
31 or positive findings in each index. The results of multivariate analyses were adjusted for the  
32  
33 age and smoking status of the subjects. Body mass index was also used as an adjustment  
34  
35 factor in the case of CRP.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Table 3. A comparison of the cumulative frequency of incidence in select biomedical indices associated with lung fibrotic changes that newly emerged during the follow-up period**

	Univariate analysis			Multivariate analysis			
	Incidence			Logistic regression model			
	Total			Total	TPD	DDM	MTN
Exposed	Controls	<i>p</i> *	OR(95%CI) <sup>†</sup>	OR (95%CI) <sup>†</sup>	OR (95%CI) <sup>†</sup>	OR (95%CI) <sup>†</sup>	
Respiratory symptoms <sup>‡</sup>							
Chronic cough (7E)	11.3	6.3	0.04	2.26(1.13-4.53)	1.88(0.82-4.31)	2.70(1.21-5.99)	2.31(1.01-5.25)
Chronic phlegm (8E)	14.0	9.6	0.12	1.6(0.91-2.83)	1.46(0.74-2.88)	1.65(0.81-3.37)	1.68(0.83-3.40)

Breathlessness #2 (13B)	6.0	4.7	0.48	1.69(0.73-3.94)	1.51(0.54-4.19)	0.94(0.27-3.25)	2.62(1.00-6.87)
Serum biomarkers							
KL6§	2.1	1.8	1.00	1.27(0.38-4.29)	2.09(0.54-8.05)	0.44(0.05-4.09)	1.25(0.26-5.94)
SPD	2.4	2.4	1.00	1.06(0.34-3.28)	0.87(0.21-3.54)	1.62(0.40-6.48)	0.94(0.21-4.24)
Pulmonary function							
FVC	15.3	13.2	0.50	1.22(0.73-2.05)	2.60(1.44-4.71)	0.54(0.24-1.21)	0.84(0.42-1.68)
FEV1	11.4	8.5	0.26	1.38(0.76-2.49)	2.43(1.24-4.76)	0.68(0.27-1.69)	1.19(0.55-2.57)
FEV1/FVC	9.9	6.8	0.20	1.59(0.81-3.09)	1.88(0.87-4.09)	1.16(0.48-2.85)	1.72(0.77-3.85)
Chest X-ray							
Non-specific findings	5.6	5.2	0.8	1.39(0.65-2.97)	1.38(0.53-3.59)	1.75(0.70-4.37)	0.98(0.34-2.80)

TPD: toner production, DDM: machine design and development, MTN: maintenance, RCL: recycling

1  
2  
3  
4  
5  
6 \* Probability under the hypothesis that there are no differences between the control group and exposed group as a whole examined by the  
7  
8 chi-squared test or Fisher's exact probability method  
9

10  
11 † Odds ratio (OR) and its 95% confidence intervals (95% CI) of the exposed group to the control group, regarding the newly emerging  
12  
13 abnormalities of biomedical indices  
14  
15

16  
17 ‡ The ATS-DLD-78A questionnaire code is shown in the parentheses.  
18

19  
20 § Fisher's exact probability method was applied.  
21

22  
23 # Grade of the severity of the symptom  
24

25  
26 The figures in the column of incidence represent the proportion of subjects starting to show symptoms or positive findings during the follow-up  
27  
28 period among those who did not have the symptom or positive finding at baseline. The results of multivariate analyses were adjusted for the age  
29  
30 and smoking status of the subjects.  
31  
32  
33  
34  
35  
36  
37  
38  
39

**Table 4.** (New) Annual decline in spirometric indices according to exposure category.

	Category of exposure condition (number of subjects)						Statistical test of the	
	Control	Exposed*					mean values†	
		Total	TPD	DDM	MTN	RCL	<i>p</i>	
Spirometric indices	(N=217)	(N=477)	(N=175)	(N=145)	(N=150)	(N=7)	Unadjusted	Adjusted‡
$\Delta$ FVC/HT <sup>2</sup> (ml/m <sup>2</sup> )	-6.2(21.4)	-4.0(19.1)	-0.7(25.8)	-2.5(12.5)	-9.0(14.3)	-5.8(13.3)	0.19	0.50
$\Delta$ FEV1/HT <sup>2</sup> (ml/m <sup>2</sup> )	-8.8(16.3)	-7.5(13.9)	-6.5(16.3)	-7.3(10.7)	-9.0(12.5)	-6.7(32.6)	0.33	0.30

\* TPD: Toner production, DDM: Machine design and development, MTN: Maintenance, RCL: Recycling

† Comparison between the control and the exposed as a whole

‡ Adjusted for age, sex, and smoking habit at the baseline.

Values are the arithmetic means and standard deviations at the point of baseline survey.

For peer review only

**Table 5. Independent contribution of confounding factors in the multivariate analyses of biomedical indices**

	Smoking		Age		BMI
	Prevalence*	Incidence†	Prevalence*	Incidence†	Prevalence*
	OR(95% CI)‡	OR(95% CI)‡	OR(95% CI)‡	OR(95% CI)‡	OR(95% CI)‡
5					
22	Cough #1 (7A) <sup>§</sup>	1.68(1.12-2.51)			
25	Cough #2 (7B) <sup>§</sup>	1.62(1.03-2.54)			
28	Chronic cough (7E) <sup>§</sup>	3.34(1.49-7.48)	1.63(1.08-2.45)		
31	10 Phlegm #1 (8A) <sup>§</sup>	2.38(1.63-3.47)			
34	Phlegm #2 (8B) <sup>§</sup>	2.62(1.60-4.29)	1.38(1.05-1.82)		
37	Chronic phlegm (8C) <sup>§</sup>	3.69(1.85-7.35)	1.80(1.10-2.96)	1.53(1.08-2.16)	



1			
2			
3			
4			
5			
6	Breathlessness #1 (13A) <sup>§</sup>	1.59(1.17-2.16)	
7			
8			
9	Breathlessness #2†(13B) <sup>§</sup>	2.64(1.36-5.12)	
10			
11	Breathlessness #3‡(13C) <sup>§</sup>	5.62(1.51-20.85)	
12			
13			
14	CRP abnormality		1.32(1.17-1.49)
15			
16			
17	5 SPD abnormality	4.10(1.15-14.58)	
18			
19			
20	Reduced FVC	3.13(1.09-8.97)	
21			
22			
23	Reduced FEV1	3.82(1.38-10.58)	
24			
25			
26	Reduced FEV1/FVC	3.92(1.20-12.87)2.11(1.27-3.52)	
27			
28			
29	Non-specific X-ray	1.59(1.06-2.38)	
30			
31	10 findings		
32			
33			
34			
35			
36			
37	* An analysis of the prevalence at baseline.		
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			

1  
2  
3  
4  
5  
6 † An analysis of the new incidence during the follow-up observation  
7


8 ‡ Odds ratio (OR) and its 95% confidence intervals (95% CI) of the exposed group to the control group, regarding the prevalence and incidence  
9  
10  
11 of biomedical indices.

12  
13  
14 § The ATS-DLD-78A questionnaire code is shown in the parentheses.  
15



16  
17 5 # Grade of the severity of the symptom  
18

19  
20 Values are presented as the OR (95% CI) estimated using the logistic regression models shown in Tables 3 and 4. Only statistically significant  
21  
22 results are shown.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



119x90mm (300 x 300 DPI)



90x112mm (300 x 300 DPI)

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies***

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6-7
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	8-10
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	10-15
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	10-15
Bias	9	Describe any efforts to address potential sources of bias	9, 10-13
Study size	10	Explain how the study size was arrived at	8-9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	15-17
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	17
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	8-9
		(e) Describe any sensitivity analyses	22-23, 48-50
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-9, 19
		(b) Give reasons for non-participation at each stage	8-9, 19
		(c) Consider use of a flow diagram	51(Fib.1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	19-20, 38-39, 52(Fig.2)
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	19
Outcome data	15*	Report numbers of outcome events or summary measures over time	21-22, 43-47
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	21-22, 43-47
		(b) Report category boundaries when continuous variables were categorized	12, 14
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	22-23, 43-45, 48-50
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	27, 31
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	29-30
Generalisability	21	Discuss the generalisability (external validity) of the study results	
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	32

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Assessing the chronic respiratory health risk associated with inhalation exposure to powdered toner for printing in actual working conditions: A cohort study on occupationally exposed workers over 10 years

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022049.R2
Article Type:	Research
Date Submitted by the Author:	19-Aug-2018
Complete List of Authors:	Nakadate, Toshio; Showa University Graduate School of Medicine School of Medicine, Hygiene, Public Health, and Preventive Medicine Yamano, Yuko; Showa University Graduate School of Medicine School of Medicine, Hygiene, Public Health, and Preventive Medicine Yamauchi, Takenori; Showa University Graduate School of Medicine School of Medicine, Hygiene, Public Health, and Preventive Medicine Okubo, Shigeko; Showa University Graduate School of Medicine School of Medicine, Hygiene, Public Health, and Preventive Medicine Nagashima, Daichi; Showa University Graduate School of Medicine School of Medicine, Hygiene, Public Health, and Preventive Medicine
<b>Primary Subject Heading</b>:	Occupational and environmental medicine
Secondary Subject Heading:	Epidemiology, Respiratory medicine
Keywords:	EPIDEMIOLOGY, OCCUPATIONAL & INDUSTRIAL MEDICINE, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Assessing the chronic respiratory health risk associated with inhalation exposure to**  
5  
6 **powdered toner for printing in actual working conditions: A cohort study on**  
7  
8 **occupationally exposed workers over 10 years**  
9  
10

11  
12  
13  
14  
15 Toshio Nakadate(1), Yuko Yamano(1), Takenori Yamauchi(1), Shigeko Okubo(1), Daichi  
16  
17 Nagashima(1)  
18

19  
20 (1) Department of Hygiene, Public Health, and Preventive Medicine, Showa University  
21  
22 School of Medicine, Tokyo, Japan  
23  
24  
25

26  
27  
28  
29 Corresponding author: Toshio Nakadate  
30

31  
32 Department of Hygiene, Public Health, and Preventive Medicine,  
33

34  
35 Showa University School of Medicine  
36

37  
38 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan  
39

40  
41 e-mail: nakadate@med.showa-u.ac.jp  
42

43  
44 Tel: +81-3-3784-8137 Fax: +81-3-3784-8251  
45

46  
47  
48  
49 Word count

50  
51  
52 Abstract: 276  
53

54  
55 Text (Introduction, Methods, Results, Discussion, Conclusion): 5259  
56



1  
2  
3  
4 Table: 5, Figure 2  
5

6  
7 References: 28  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Abstract**

**Background:** Little epidemiological evidence exists regarding the chronic respiratory effects of inhaled powdered toner exposure in humans, although several case reports have suggested the existence of lung disorders that might be related to exposure to toner dust.

**Objective:** We aimed to estimate the chronic health risk to humans associated with routine toner dust exposure in copier-industry workers under current actual work conditions.

**Design:** A prospective observational cohort study of occupational population.

**Methods:** Changes in chest radiogram, spirometry measurements, and serum and urine biomarkers of biomedical responses to extrinsic stress, as well as subjective symptoms were longitudinally observed for up to 10 years in Japanese copier-industry workers responsible for the manufacturing, maintenance or recycling of powdered toner or toner-using machines. A total of 694 subjects who did not change their work category during the follow-up and were free from chronic respiratory diseases at the baseline survey provided reliable results on at least 3 survey occasions during 3 years or more of follow-up.

**Results:** Typical fibrosis findings associated with pneumoconiosis was not observed on chest radiograms. No significant differences associated with toner exposure were noted in the frequency of new incidence of either non-specific findings on chest radiogram or serum fibrosis biomarkers (KL6 and SPD). However the exposed subjects tended to show increases in the frequency of respiratory symptoms and reduced spirometry results during the follow-up

1  
2  
3  
4 compared with the control group, although significant differences were only seen in chronic  
5  
6 cough.  
7

8  
9 **Conclusions:** Under the current reasonably controlled work environmental conditions, lung  
10  
11 fibrotic changes caused by inhaled dust exposure, including powdered toner, appear to be  
12  
13 relatively uncommon; however, nonspecific temporal irritation causing subjective symptoms  
14  
15 and inflammatory responses might exist.  
16  
17  
18  
19  
20  
21  
22

23 Key words: Dust, Longitudinal studies, Respiratory, Epidemiology  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- An occupational cohort of workers in business machine industry exposed to printing toner dust in various types of work was followed for up to 10 years regarding their respiratory health status on an annual basis, mainly focusing on lung fibrotic changes.
- The incidence of newly emerging lung fibrotic changes was compared between the exposed workers and the non-exposed controls using wide-range health outcomes including chest X-ray findings, lung function results, and serum and urine biomarkers, as well as subjective symptoms.
- The total dust exposure during toner handling was measured in a representative sample of workers, but the fraction of toner particles in the whole dust exposure cannot be estimated accurately.
- Conventional chest radiography was utilized to evaluate lung fibrotic changes in an epidemiological research setting; however, computed tomography (CT) might have been more sensitive to early minimal fibrotic changes.
- Healthy worker bias might exist because some portion of the cohort ceased participation during the follow-up due to resigning, retiring, or transferring, although no toner-related health problems, such as lung fibrosis, were reported among these subjects.

## Introduction

Possible harmful effects of inhaled photocopier toner dust have been a matter of concern since the publication of several case reports suggesting the existence of toner-related pulmonary disorders [1][2][3]. However, little evidence is available regarding the potential for toner dust inhalation in occupational and general home environments where photocopier machines and laser printing devices are in use.

We reported the results of a cross-sectional study of toner-handling workers engaged in several types of toner exposure work [4]. Although the results suggested the limited possibility of adverse effects due to toner dust inhalation, it was also suggested that a study with longitudinal design would be useful for a more detailed examination of the hypothesized association between toner dust exposure and adverse health effects under current actual work conditions.

We therefore conducted a longitudinal study of toner-handling workers for 10 years in a business machine-producing company and affiliated companies involved in maintaining and recycling these machines in order to obtain longitudinal evidence to determine a possible health risk associated with a practical level of toner dust exposure under current actual work conditions, with particular focus on chronic fibrotic changes in the lungs.

This is the first report of this study and mainly presents the results of analyses of the

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

possible chronic health effects, including lung fibrotic changes as the principal research target, associated with toner dust exposure under current actual work conditions based on longitudinally observed health data.

For peer review only

## Methods

### *Subjects*

The subjects were employees of seven branches of a group of companies that produced, maintained, and recycled photocopiers, laser printers, and related products for printing with the use of powdered toner. We identified four categories of toner-handling work among the subjects. Toner production (TPD) represents work associated with any process in the course to producing powdered toner, such as mixing and molding raw materials, crushing toner mass, and filling and packing the products. Designing and development of machines (DDM) represents work associated with developing new models of toner-using business machines, in which various types of toner-handling procedures are involved. Maintenance (MTN) represents the work associated with maintaining photocopiers and laser printers in users' offices and homes. Recycling (RCL) represents work associated with processing recycled toner cartridges. The air environment was generally well-maintained using local ventilation instruments according to the regulations in Japan. The workers were therefore encouraged to wear respiratory protection masks in only limited situations where heavy exposure might occur, such as when cleaning the mixing tanks or performing maintenance on/repairing equipment.

The survey on the health status of the subjects started in the fall of 2003 and was

1  
2  
3  
4 repeated until 2013 basically on an annual basis in the same manner as the first one in 2003.  
5  
6 Throughout the entire study period, a total of 1176 toner handling workers (587 for TPD, 207  
7  
8 for DDM, 346 for MTN, and 36 for RCL) participated in at least one of these surveys.  
9  
10 However, some participants ceased participation during an early stage of the study for various  
11  
12 reasons other than toner-related health problems (e.g. resigning, retiring, or transferring), and  
13  
14 others started participating in a later stage of the study. Therefore, we defined the subjects  
15  
16 with a sufficient follow-up duration for a longitudinal data analysis in this paper as those who  
17  
18 started participating by the spring of 2005 and were followed-up for three years or more with  
19  
20 at least three surveys throughout the entire study period. In addition, subjects were those who  
21  
22 had not changed their work category (concerning the presence or absence of toner handling)  
23  
24 during their follow-up. The flowchart in Fig. 1 shows the number of participants included in  
25  
26 or excluded from the analysis based on the above-mentioned criteria.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 The number of toner workers who met the above criteria was 487. As a reference  
38  
39 population for comparison with these toner-handling workers, an additional 309 control  
40  
41 subjects who had never participated in any types of toner-handling work described above also  
42  
43 participated in this study by the spring of 2005. Among them, the 223 who met the same  
44  
45 criteria as exposed workers stated above were analyzed. Control subjects were recruited at  
46  
47 each participating branch and amounted to roughly half the number of toner-handling  
48  
49 workers. The control subjects basically worked in different buildings from the ones where the  
50  
51  
52  
53  
54  
55  
56



1  
2  
3  
4 exposed workers were engaged in toner-handling work. While the control subjects  
5  
6 occasionally happened to enter the factory area, such accidental exposure was quite limited.  
7  
8  
9

### 10 11 12 *Health status indices*

13  
14  
15 Subjects' health status was evaluated on an annual basis from various health-related aspects  
16  
17 using physiological, biochemical, and radiographic examination tools as well as via the  
18  
19 assessment of subjective symptoms and clinical signs. This evaluation focused mainly on  
20  
21 chronic respiratory deterioration, including pulmonary fibrotic conditions, and biological  
22  
23 responses to inhaled potentially harmful substances. Standardized methods were utilized for  
24  
25 health status measurement to keep the measurement bias as small as possible. The biomedical  
26  
27 indices examined in this study are described below.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 *Chest X-ray findings*

39  
40 Chest radiography was carried out to obtain a standardized anterior-posterior X-ray film by  
41  
42 using prescribed standard procedures to detect mineral-dust pneumoconiosis in Japan [5].  
43  
44 Each X-ray film was read by one of three readers with sufficient experience in the  
45  
46 radiographic diagnosis of pneumoconiosis while referencing the standard films for the  
47  
48 diagnosis [6]. The readers were privy to no information regarding the exposure status of the  
49  
50 subjects. The severity of fibrotic findings in the lung fields was classified into 12 grades,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 from 0/- to 3/+, according to the distribution and density of the small opacities. This  
5  
6 classification was compatible with that of the International Labor Organization (ILO) [7].  
7  
8  
9 However, we noted none of the fibrotic findings typically observed in mineral dust  
10  
11 pneumoconiosis cases with 1/1 or a more severe grade profusion during early surveys.  
12  
13  
14 Therefore, we additionally recorded mild, non-specific findings, such as sparse irregular  
15  
16 opacity, unclear interstitial shadow, or disrupted vascular shadow in radiographs. These  
17  
18 findings were not only potentially related to early effects of toner toxicity but also might be  
19  
20 caused by acute or sub-acute non-specific irritation or infection, which might be reversible.  
21  
22  
23  
24  
25  
26  
27  
28

### 29 *Questionnaire survey*

30  
31  
32 Detailed information regarding respiratory symptoms, allergic symptoms, past and present  
33  
34 medical history, and lifetime smoking history was obtained using a translated version of a  
35  
36 self-administered questionnaire standardized by the American Thoracic Society  
37  
38 (ATS-DLD-78A) [8], with slight modification and several additional questions on allergies of  
39  
40 the eye, nose, and skin. The responses were certified by several trained interviewers, and  
41  
42 supplemental interviews were held when necessary. Subjects were considered to have a  
43  
44 symptom when they gave an affirmative response to questions about the specific symptom.  
45  
46  
47  
48  
49 The lifetime work history was also confirmed during this interview.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Spirometry*

Subjects were asked to repeat the forced expiratory maneuver up to a maximum of five times in the standing position in order to obtain acceptable and reproducible spirometry results. The mechanical specifications of the spirometer used (DISCOM-21FX2; CHEST Co. Ltd., Tokyo, Japan) met the standards stipulated by ATS [9]. Routine BTPS correction and back-extrapolation were carried out. The calibration of the spirometer, spirometry measurements, and evaluation of the results were based on prescribed procedures described in detail elsewhere [10].

The percent predicted values standardized on sex, age, and height were calculated for forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and FEV1/FVC in each subject based on the prediction equations published by the Japanese Respiratory Society [11]. The values of FVC, FEV1, and FEV1/FVC were defined as reduced when they were smaller than the lower value of the confidence interval of the authorized reference equations described above. All figures were calculated from the best maneuver yielding the largest sum of FVC and FEV1 for each subject [12].

For the analysis of the longitudinal changes in spirometry indices, we calculated the height-squared proportional values of FVC ( $FVC/HT^2$ ) and FEV1 ( $FEV1/HT^2$ ) to adjust for differences in the body size. The annual decline in  $FVC/HT^2$  and  $FEV1/HT^2$  were calculated for each subject as a regression coefficient using a simple linear regression equation of those

1  
2  
3  
4 values against age during the follow-up period.  
5  
6  
7

8  
9 *Serum and urine biomarkers*  
10

11  
12 Peripheral venous blood and urine (10 and 20 ml, respectively) were obtained from each  
13  
14 subject at the time of every survey. Serum was immediately separated from whole blood  
15  
16 sample using a routine procedure. Then, serum and urine samples were deeply frozen at  
17  
18 -80 °C until analyses were carried out.  
19  
20  
21  
22

23  
24 As the indices of biological responses to inhaled extrinsic irritants like toner particles,  
25  
26 we employed the following biomarkers: highly sensitive C-reactive protein (CRP),  
27  
28 non-specific immunoglobulin E (IgE), sialylated carbohydrate antigen KL-6 (KL6), and lung  
29  
30 surfactant protein D (SPD) in serum, and 8-hydroxy deoxy guanosine (8OHdG) in urine. In  
31  
32 Japan, serum CRP, IgE, KL6, and SPD levels are routine clinical laboratory test items  
33  
34 assessed in common medical practice. The analyses of those results were therefore carried out  
35  
36 according to the appropriate Standard Operation Procedures (SOP) in SRL Inc., Tokyo.,  
37  
38 Japan which has been providing high quality testing under the certification of the Japan  
39  
40 Accreditation Board, a public service juridical foundation for ensuring the reliability of  
41  
42 clinical laboratory testing in Japan.  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 Urine 8OHdG was measured using an ELISA kit (New 8OHdG Check ELISA Kit;  
53  
54 Japan Institute for the Control of Aging) and was adjusted for urine condensation using the  
55  
56

1  
2  
3  
4 urine creatinine concentration as the denominator.  
5

6 The result of the measurement of each index was judged to be out of the normal range  
7  
8 when the value exceeded the following figures: 1500 ng/ml for CRP, 173 IU/ml for IgE,  
9  
10 500 U/ml for KL6, 110 ng/ml for SPD, and 20 ng/mg creatinine for 8OHdG.  
11  
12  
13  
14

### 15 16 17 18 *Exposure assessment*

19 We directly measured the personal exposure levels in individual toner-handling workers.  
20  
21

22 The average diameter of the toner particles contained in the products handled by the workers  
23  
24 in this study was about 10  $\mu\text{m}$ . Workers were asked to wear a portable personal dust sampler  
25  
26 (NWPS-254 sampler with a T60A20 sampling filter, SIBATA SCIENTIFIC TECHNOLOGY  
27  
28 Ltd., Tokyo, Japan) that continuously sampled the air in the workplace environment at 2.5  
29  
30 L/min air flow driven by a MP-2N or MP-3 $\Sigma$  pump (SIBATA SCIENTIFIC TECHNOLOGY  
31  
32 Ltd., Tokyo, Japan). The sampling head was located around the neck of each subject to  
33  
34 collect particles suspended in the air throughout a given period of toner-related work. The  
35  
36 respirable fraction was separated using filters designed to cut 50% of 4- $\mu\text{m}$ -diameter particles.  
37  
38 The concentration of total and respirable dust exposed to the workers was calculated as a  
39  
40 time-weighted average value for 8 h (TWA-8h) based on the amount of dust collected on the  
41  
42 filter and the total volume of air inspired by the sampling pump. Measurements were  
43  
44 conducted basically twice a year for at least 5 workers in each toner-handling procedure,  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 yielding a total of 2042 measurements (1751 for TPD, 81 for DDM, 88 for MTN, and 122 for  
5  
6 RCL) throughout the study period. Those values obtained were evaluated with reference to  
7  
8 the recommendations by the Japan Association of Industrial Health (JAIH) [13]. We also  
9  
10 analyzed several chemical components that were generated when the toner was heated at a  
11  
12 temperature of around 180 degrees centigrade as representative components of powdered  
13  
14 toner using gas chromatography and mass spectrometry (GC-MS) in order to estimate the  
15  
16 toner exposure separately from other types of dusts suspended in the air. However, we were  
17  
18 unable to obtain reliable estimates of the amount of toner dust fraction in the whole dust  
19  
20 cluster collected on the sampling filter, mainly because of large variability of the values  
21  
22 depending on the types of toner handled.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 *Analyses*

- 36  
37 • Cross-sectional evaluation of baseline data

38  
39 For each subject, we considered the results obtained in the first year of participation as the  
40  
41 baseline data, indicating the condition at the beginning of the longitudinal observation of this  
42  
43 study. The relative frequency of subjects with positive results was calculated for each  
44  
45 health-related item described above (prevalence) and compared statistically between the  
46  
47 exposed subjects as a whole and the control subjects. The significance of differences in the  
48  
49 prevalence between the exposed subjects and controls was assessed using a chi-squared test  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 and Fisher's exact test as appropriate. A multiple logistic regression analysis was used to  
5  
6 obtain the OR estimates adjusted for possible confounding factors.  
7  
8  
9

- 10  
11  
12 • Longitudinal evaluation of chronic fibrotic findings  
13

14  
15 For the longitudinal analysis, we mainly focused on the results associated with chronic  
16  
17 respiratory toxicity, including the fibrotic potential of toner dust inhalation exposure. To this  
18  
19 end, we analyzed the changes in chest radiographic findings during the follow-up period. We  
20  
21 also used three pulmonary function indices (FVC, FEV1, and FEV1/FVC) and two serum  
22  
23 biomarkers (KL6 and SPD, both of which are recognized as useful markers of active-phase  
24  
25 fibrotic conditions in the lungs) [14]. In addition, we selected three chronic respiratory  
26  
27 symptoms associated with chronic respiratory diseases, such as fibrotic lung changes, namely  
28  
29 chronic cough, chronic phlegm, and breathlessness. Chronic cough, as well as chronic  
30  
31 phlegm, was considered to be present when the symptom existed for three months or more in  
32  
33 a year. Breathlessness was considered to be present when a subject walked slower than their  
34  
35 counterparts of the same age on level ground.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 In the longitudinal data analysis, we evaluated the frequency of abnormalities that  
47  
48 newly emerged during the follow-up observation (incidence). Abnormalities were considered  
49  
50 to be present when the respiratory symptom or the X-ray findings were newly noted or when  
51  
52 the pulmonary function or biomarker values exceeded the normal range during follow-up.  
53  
54  
55  
56

1  
2  
3  
4 Therefore, those subjects who already had abnormalities at their baseline survey were  
5  
6 excluded from the longitudinal data analysis. The incidence was compared between the  
7  
8 exposed workers as a whole and the control subjects, as well as by the work categories. In a  
9  
10 similar manner to the cross-sectional analyses, the incidence was compared using a  
11  
12 chi-squared test or Fisher's exact test as appropriate, and the OR estimates adjusted for  
13  
14 confounders were calculated using a multiple logistic regression analysis.  
15  
16  
17  
18  
19  
20  
21  
22

### 23 *Statistical analyses*

24  
25  
26 For comparisons by exposure categories, the chi-squared test and Fisher's exact test as well as  
27  
28 a multiple logistic regression analysis were performed for categorical variables, and a simple  
29  
30 *t*-test and an analysis of covariance were performed for numeric variables, with the alpha  
31  
32 error level set at 0.05. All statistical tests and estimations were carried out using the SAS  
33  
34 statistical package on a personal computer (PC-SAS Version 9.2; SAS Institute Inc., Cary, NC,  
35  
36 USA).  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 *Ethical considerations*

47  
48 The objectives and outline of the study were explained to the subjects at the beginning of the  
49  
50 study, and written informed consent was obtained from each participant. All information  
51  
52 obtained in this study was handled in accordance with the guidelines for epidemiological  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 studies authorized in Japan [15]. This study was conducted under the approval of the  
5  
6 Institutional Review Board on Medical Ethics of Showa University School of Medicine  
7  
8  
9 (Authorization No. 201).  
10

11  
12  
13  
14  
15 *Patient involvement*  
16

17 Patients were not involved in this study.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

As stated earlier, we selected 710 workers (489 exposed and 221 controls) as the subjects for this longitudinal data analysis. Among them, 16 subjects reported that they had suffered from chronic respiratory diseases prior to the beginning of this study (chronic obstructive pulmonary disease and/or pulmonary tuberculosis). These subjects were therefore excluded, and the remaining 694 subjects were ultimately analyzed (Fig. 1). The average number of surveys in which those subjects participated was 6.8, and the average follow-up duration (elapsed time from the first observation to the final one) was 7.4 years. No significant difference was observed in those average values between the exposed and control groups.

Several background characteristics at the baseline point, as well as the results of personal exposure measurements during the entire study period as the 10th and 90th percentile values of the TWA-8h concentration, were compared among the exposure categories in Table 1. The male to female ratio was comparable between the exposed and control groups. However, the absolute number of female subjects was quite small compared to males, with only 28 women analyzed. Significant differences were observed between the exposed and control groups in mean age and smoking habit classification at the baseline survey, with the exposed group being younger and more likely to smoke than the controls. Seventy-six of 360 current smokers at baseline quit smoking during their follow-up period,

1  
2  
3  
4 whereas only 1 out of 220 never smokers at the point of baseline started smoking during the  
5  
6 follow-up. As for body size, the mean values of standing height and body mass index (BMI)  
7  
8 were comparable between the exposed and control groups.  
9  
10

11  
12 The TPD and RCL workers tended to show higher percentile values both in the total  
13  
14 and respirable TWA-8h than the DDM and MTN workers. As suggested by those summary  
15  
16 percentile values, the individual TWA-8h values distributed across a rather wide range, and  
17  
18 some of them exceeded the permissible limit recommended by JAIH (4 mg/m<sup>3</sup> as total and 1  
19  
20 mg/m<sup>3</sup> as respirable carbon black dust, and 8 mg/m<sup>3</sup> as total and 2 mg/m<sup>3</sup> as respirable  
21  
22 general dust) [13]. However, the overall median TWA-8h values of both total and respirable  
23  
24 dust were well below the JAIH recommendations, even among the TPD and RCL workers.  
25  
26 Fig. 2 shows the time-dependent change in those summary statistics of personal exposure  
27  
28 measurement during the study period. No marked trends were observed in the percentile  
29  
30 values during the 10-year follow-up, suggesting that the work environment was relatively  
31  
32 stable throughout the study period in terms of dust exposure to the workers as a whole.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 Table 2 summarizes the prevalence of the biomedical indices studied at the baseline  
44  
45 survey according to the exposure categories. The odds ratios (ORs) and their 95% confidence  
46  
47 intervals (CIs) of the exposed to the control group are also shown after adjustment for  
48  
49 possible confounding variables. The exposed group tended to show higher prevalence in  
50  
51 respiratory symptom indices, although significant differences were observed only in chronic  
52  
53  
54  
55  
56

1  
2  
3  
4 phlegm and wheeze grade 2. The prevalence values for CRP and IgE abnormalities were also  
5  
6 significantly larger in the exposed group than in the control group, although the results of  
7  
8 KL6 and SPD were comparable between the two groups. The difference in CRP remained  
9  
10 significant even after adjustment for BMI, a well-known contributor to the serum CRP level.  
11  
12  
13  
14 Only a small number of subjects demonstrated values outside of the reference ranges of FVC,  
15  
16 FEV1 or FEV1/FVC, and the prevalence showed values ranging from 2 to 6 %. There were  
17  
18 no cases of clear pneumoconiosis with 1/1 or a more severe grade on baseline chest X-ray  
19  
20 films of the subjects analyzed, although non-specific findings were noted in 3.4% of the  
21  
22 exposed and 1.8% of the control subjects at baseline. No significant difference between the  
23  
24 two groups was noted in the prevalence at baseline of either the pulmonary function or chest  
25  
26 X-ray indices.  
27  
28  
29  
30  
31  
32  
33

34  
35 Table 3 compares the frequency of newly emerging abnormalities observed during the  
36  
37 follow-up period between the exposed and control groups for selected biomedical indices in  
38  
39 order to examine the degree of chronic respiratory deterioration, including lung fibrotic  
40  
41 changes. This table also includes the results of comparisons according to work categories,  
42  
43 although no RCL workers were included in this analysis because the number of such workers  
44  
45 was too small; namely, only seven workers. After carefully evaluating the chest X-ray films  
46  
47 accumulated during the follow-up period, we observed no cases with 1/1 or a more severe  
48  
49 grade of pneumoconiosis. In addition, the incidence of non-specific findings during the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 follow-up was comparable between the exposed and control groups. Furthermore, two  
5  
6 clinically useful biomarkers of lung fibrosis (KL6 and SPD) showed rather low incidence  
7  
8 values for newly emerging abnormalities, which were comparable between the exposed and  
9  
10 control groups. However, regarding symptoms and the pulmonary function, the exposed  
11  
12 group tended to have a higher incidence of abnormalities more frequently than the control  
13  
14 group. The ORs estimated by logistic regression analyses mostly exceeded 1.5, and after  
15  
16 adjustment for age and smoking status during the follow-up period, chronic cough emerged  
17  
18 significantly more frequently in the exposed subjects than in the control group. In the  
19  
20 analyses according to work categories, an increase in the OR value of chronic cough was  
21  
22 observed in all exposed work categories that were analyzed, and reaching a statistically  
23  
24 significant level in DDM and MTN workers. The TPD, the highest exposure category, tended  
25  
26 to show a more consistent elevation of OR values versus the controls than other work  
27  
28 categories.

29  
30  
31  
32 Table 4 shows the comparison of  $FVC/HT^2$  and  $FEV1/HT^2$  decline during the  
33  
34 follow-up period among the exposure categories. Comparable values were obtained for both  
35  
36 indices between the exposed as a whole and the control groups. After adjustment for the  
37  
38 significant contribution of age, toner exposure was not a significant factor influencing the  
39  
40 decline in the pulmonary function. In the comparison among the three exposed work  
41  
42 categories the MTN workers showed a larger annual decline in both  $FVC/HT^2$  and  $FEV1/HT^2$   
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 than TPD and DDM workers, although the differences were not statistically significant after  
5  
6 adjusting for age.  
7

8  
9 Table 5 summarizes the significant independent contribution of confounding factors in  
10  
11 the multivariate analyses described in Tables 2 and 3 as estimated ORs for the health-related  
12  
13 outcomes. Only statistically significant results are presented with their 95% CIs. Smoking  
14  
15 was considered to increase the incidence of chronic phlegm, SPD abnormality, and reduced  
16  
17 FVC and FEV1 during follow-up, as well as the prevalence of many symptoms and a reduced  
18  
19 pulmonary function at baseline. Similar increases in ORs with age were also observed for the  
20  
21 incidence during the follow-up and the prevalence at baseline of some of the examined  
22  
23 indices. A clear independent association between serum CRP abnormalities and obesity was  
24  
25 also observed.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

Photocopiers and laser printers using powdered toner are widely used in offices and homes, but the powdered toner for printing and emissions from these machines may become air pollutants in office and home environments [16][17]. McGarry et al. reported the condition of particulate air pollution resulting from the use of laser printers in several actual office environments [18]. As several case reports have suggested the existence of chronic pulmonary disorders possibly associated with inhaled toner dust [1][2][3], many aspects of toner-related health effects have been reported. Khatri et al. [19] conducted a human volunteer exposure study in an actual current office environment and found that several biomarkers, including 8OHdG as a marker of oxidative stress [20], changed in relation with the particulate air pollutants emitted by photocopiers and laser printers, although those changes were acute or sub-acute and not chronic in nature. Elango et al. [21] reported the result of a cross-sectional study on photocopier center workers in India, showing the significant elevation of serum inflammatory biomarkers among the exposed workers compared with the controls. Kasi et al. [22] suggested possible genotoxicity associated with photocopier-related exposure in a survey of photocopier operators and maintenance workers. Yanagi et al. [23] found no marked difference in the pulmonary function due to toner-related work in their cross-sectional analysis of workers at a business equipment manufacturer. In their critical review, Pirela et al. [24] stated that particulate matter, including nanoparticles

1  
2  
3  
4 emitted from photocopiers and laser printers during operations, could exert biological effects  
5  
6 on the respiratory system, such as oxidative stress and inflammatory responses.  
7

8  
9 Compared with human volunteer or cross-sectional epidemiological studies, the  
10  
11 evidence obtained by longitudinal epidemiological studies is quite limited, but longitudinal  
12  
13 study results are needed to fully examine the health impact of particulate air pollutants  
14  
15 associated with office machines, as far as chronic health effects are concerned. In a cohort  
16  
17 study on toner and photocopier manufacturing workers conducted over four years, no  
18  
19 evidence was obtained regarding the adverse effects on the pulmonary function or chest  
20  
21 X-ray findings associated with toner-handling work [25][26], although an increased  
22  
23 prevalence of breathlessness was observed in association with toner-handling work [27].  
24  
25 However, those studies did not evaluate the incidence of abnormalities based on  
26  
27 longitudinally observed data. Therefore, we conducted a longitudinal study to further  
28  
29 evaluate the possible health effects of toner dust exposure as a subsequent study of our  
30  
31 cross-sectional one mentioned above [4] with a focus mainly on the chronic respiratory  
32  
33 effects, such as lung fibrotic changes. To determine the actual risk in the current real-world  
34  
35 environment, we studied an actual working population. Personal exposure measurement  
36  
37 results showed that the current level of exposure to total and respirable dust in toner-handling  
38  
39 workers was on average well below the permissible exposure levels of general mineral dust  
40  
41 and carbon black dust recommended by JAIH [13], even among TPD and RCL workers, in  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56



1  
2  
3  
4 whom relatively high exposure was observed. We also used several biomedical indices to  
5  
6 detect possible harmful effects on the respiratory system: namely imaging findings by chest  
7  
8 X-ray, KL6 and SPD levels in serum as clinically utilized biomarkers on lung fibrosis,  
9  
10 spirometry results to evaluate the lung functional status, and subjective symptoms obtained  
11  
12 through standardized methods.  
13  
14  
15  
16  
17

18 In a cross-sectional analysis of the baseline results, the exposed group tended to have  
19  
20 subjective symptoms more frequently than in the control group, and similar group differences  
21  
22 were observed in the frequency of abnormal values in the majority of the biomedical indices  
23  
24 examined. In addition, the difference between the two groups reached a statistically  
25  
26 significant level in several items, even after controlling for confounders. This tendency was  
27  
28 basically consistent with what we had previously reported, with exposed workers  
29  
30 complaining of symptoms more frequently than control workers despite having a comparable  
31  
32 frequency of pulmonary function and chest radiography abnormalities. Although the presence  
33  
34 of consistent difference between the groups might suggest the existence of certain subclinical  
35  
36 changes, the cross-sectional evaluation at the baseline might have been influenced by a  
37  
38 number of factors prior to the start of this study. Therefore, newly emerging abnormalities  
39  
40 during follow-up should be examined in subjects without any abnormalities at the baseline  
41  
42 observation, as far as the chronic health effects are concerned. One interesting finding of the  
43  
44 cross-sectional analysis was the higher prevalence of CRP abnormalities, a sensitive marker  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 of acute inflammatory status in the body, among the exposed subjects compared with control  
5  
6 subjects. It seems unlikely that the elevated CRP values were significantly influenced by  
7  
8 events in the past due to its nature as an acute inflammatory biomarker. In addition, the  
9  
10 difference seemed to be independent of inflammatory conditions caused by obesity or  
11  
12 smoking, as both were used as adjustment factors in the logistic regression model. These  
13  
14 findings suggest that acute inflammatory conditions might be associated with current toner  
15  
16 exposure. At the same time, an increase in the serum IgE level was also frequently found in  
17  
18 the exposed subjects. In Japan, an allergy to cedar pollen is commonly observed every spring,  
19  
20 so cedar pollenosis may be related to the findings for CRP and IgE. However, as there are  
21  
22 multiple factors affecting the CRP [28] as well as the IgE levels, we were unable to specify  
23  
24 the reason for that group difference.  
25  
26  
27  
28  
29  
30  
31  
32  
33

34  
35 In the longitudinal analyses of biomedical indices, we evaluated the frequency of a  
36  
37 newly emerging abnormality during the follow-up period by excluding the subjects from the  
38  
39 analysis if they already had the finding at baseline. Among the indices associated with lung  
40  
41 fibrotic changes, we found closely similar results between the exposed and control groups  
42  
43 regarding the new incidence of chest radiographic findings and serum biomarker  
44  
45 abnormalities. These results suggest that the fibrogenic potential of dust exposure associated  
46  
47 with toner-handling work seems to be minimal, if any at all, as far as the current working  
48  
49 environment is concerned.  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 In contrast, the estimated ORs for FEV1/FVC abnormality adjusted for confounders  
5  
6 showed a relatively a large value exceeding 1.5, although the increase was not statistically  
7  
8 significant. A statistically significant increase in the OR of TPD versus the controls was  
9  
10 observed in FVC and FEV1 abnormalities. However, the overall differences in the incidence  
11  
12 of reduced FVC and FEV1 were relatively small between the exposed subjects and control  
13  
14 subjects. Furthermore, the annual declines in the  $FVC/HT^2$  and  $FEV1/HT^2$  of the exposed  
15  
16 subjects during the follow-up period were comparable to those of the control subjects after  
17  
18 controlling for the age and smoking status during the follow-up. Thus, it seems difficult to  
19  
20 attribute certain biological or medical reasons to the moderate, but a insignificant elevation in  
21  
22 ORs that was seen regarding the pulmonary function index abnormality. Some fluctuation  
23  
24 around normal ranges might be partially responsible for the observed elevation in OR values.  
25  
26 In the case of chronic cough, the exposed group showed a larger incidence than the control  
27  
28 group. This finding was not associated with the findings for chronic phlegm, which showed a  
29  
30 comparable incidence after adjusting for the significant contribution of smoking. This  
31  
32 suggests that the significant increase in the rate of chronic cough cannot be attributed to  
33  
34 mucus hypersecretion. Given the findings at baseline mentioned earlier, it might be possible  
35  
36 to hypothesize that non-specific irritation leading to subjective symptoms, fluctuation in the  
37  
38 pulmonary function, and inflammatory response were caused to some extent by exposure  
39  
40 associated with toner-handling work.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 However, of note: in all indices selected for the longitudinal incidence analyses, the  
5  
6 OR value adjusted for confounders exceeded the unit value without exception, suggesting  
7  
8 mostly non-significant but consistent elevation of the incidence in the exposed workers.  
9  
10 Therefore, further epidemiological studies are needed in order to identify mild and  
11  
12 nonspecific effects in a large-scale sample with sufficient statistical power. In this context, a  
13  
14 similar tendency toward a consistent OR elevation was observed in TPD work, which was  
15  
16 associated with the greatest exposure of total and respirable dust in the personal exposure  
17  
18 measurement. In the comparison of the pulmonary function decline, the largest annual losses  
19  
20 of FVC/HT<sup>2</sup> and FEV1/HT<sup>2</sup> were seen in the MTN category, where the degree of dust  
21  
22 exposure was smaller than that for TPD. However, it was difficult to perform a detailed  
23  
24 analysis by the work exposure categories with regard to the degree of toner exposures, as no  
25  
26 information was obtained regarding the exact percentage of toner included in the total dust  
27  
28 sampled. The toner particle exposure should be measured separately from other substances in  
29  
30 future studies in order to enable detailed analyses of the dose-response relationship as well as  
31  
32 to facilitate focusing on specific work categories, such as TPD and MTN.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Several limitations associated with the present study warrant mention. First, the  
47  
48 number of subjects of this study (694 in total) might be insufficient to detect minimal and  
49  
50 subclinical health deteriorations, although this study seems to have reasonably sufficient  
51  
52 power to detect at least well-established health risks, such as aging, smoking, and obesity. A  
53  
54  
55  
56

1  
2  
3  
4 meta-analysis of the studies with a common methodological basis will be useful for detecting  
5  
6 minimal effects of toner dust. Second, we obtained measurements on personal exposure  
7  
8 concentration for each work category as an exposure assessment. However, the results  
9  
10 showed large variability. In addition, we were unable to obtain reliable data on the relative  
11  
12 content of toner as a fraction of the whole dust sample. We therefore cannot reliably estimate  
13  
14 the amount of personal exposure to toner dust for each individual subject. An analysis of the  
15  
16 dose-response relationship will require a more precise exposure assessment for toner dust.  
17  
18 Third, we simply utilized conventional chest radiography and did not use computed  
19  
20 tomography (CT) to evaluate lung fibrotic changes, because we should minimize the amount  
21  
22 of X-rays that the participants were exposed to in an epidemiological research setting. We  
23  
24 were therefore unable to distinguish the non-specific findings in cases where  
25  
26 extremely-early-phase of toner-related changes might have been included. Advanced  
27  
28 radiography techniques will be useful for the more precise evaluation of lung fibrotic  
29  
30 deterioration caused by toner dust inhalation.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conclusion

Under the current reasonably controlled work environmental conditions, lung fibrotic changes caused by inhaled dust exposure, including powdered toner, appear to be relatively uncommon; however, nonspecific temporal irritation causing subjective symptoms and inflammatory responses might exist. Further epidemiological research will be useful for clarifying the possible health effects of toner dust exposure fully, especially the minimal and non-specific health changes in a study setting with a sufficient sample size to detect these changes.

## Acknowledgments

The authors thank all the subjects, investigators and survey staff who participated in this longitudinal study over 10 years.

## Footnotes

**Contributors:** TN designed the study; TN and YY executed the data collection in annual surveys; YY, TY, SO and DN contributed to the data preparation and analyses; TN wrote the initial manuscript. All of the authors contributed to the revision of the manuscript and approved the final form of the manuscript for submission.

**Funding:** This study was funded in part by Ricoh Co., Ltd., a photocopier industry company in Japan.

**Competing interest:** The authors report no conflicts of interest for the submitted work.

**Data sharing statement:** No additional data available.

## References

- [1] Gallardo M, Romero P, Sanchez-Quevedo MC, Lopez-Caballero JJ. Siderosilicosis due to photocopier toner dust. *Lancet* 1994 Aug 6;344(8919):412-3.
- [2] Armbruster C, Dekan G, Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust. *Lancet* 1996 Sep 7;348(9028):690.
- [3] Wieriks J. Photocopier toner dust and lung disease. *Lancet* 1996 Nov 30;348(9040):1518-9.
- [4] Nakadate T, Yamano Y, Adachi C, Kikuchi Y, Nishiwaki Y, Nohara M, Satoh T, Omae K. A cross-sectional study of the respiratory health of workers handling printing toner dust. *Occup Env Med* 2006;63:244-9.
- [5] Department of Health and Safety. Ministry of Labour, Japan. *Jinpai Shinsa handbook (Pneumoconiosis examination handbook)*. Tokyo: Japan Safety and Health Association, 1978. (In Japanese)
- [6] Ministry of Labour, Japan. *Jinpai Hyoujun x-ray films (Standard x-ray films for diagnosis of pneumoconiosis)*. Tokyo: Japan Safety and Health Association, 1982. (In Japanese)
- [7] International Labour Organization. *International Classification of Radiographs of Pneumoconioses (Revised, 2000)*. 2002.
- [8] Ferris BG. Epidemiology standardization project. *Am Rev Respir Dis* 1978;118(6, 2 of 2



parts):57-62.

[9] American Thoracic Society. Standardization of Spirometry, 1994 Update. *Am J Respir Crit Care Med* 1995;152:1107-36.

[10] Nakadate T, Aizawa Y, Yagami T, Zheng YQ, Kotani M. Change in obstructive pulmonary function as a result of cumulative exposure to welding fumes as determined by magnetopneumography in Japanese arc welders. *Occup Environ Med* 1998;55:673-7.

[11] Kubota M, Kobayashi H, Quanjer PH, Omori H, Tatsumi K, Kanazawa M; Clinical Pulmonary Functions Committee of the Japanese Respiratory Society. Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values. *Respir Investig*. 2014 Jul;52(4):242-50).

[12] Nakadate T. Longitudinal observation of pulmonary function decline in male Japanese workers: design, baseline results, and methodological considerations of handling pulmonary function data. *Ind Health* 1998;36:305-11.

[13] Japan Association of Industrial Health. Recommendation on threshold limit values, Japan (2016). *Sangyo Eiseigaku Zasshi* 2016;58(5):181-212. (In Japanese)

[14] Hermans C, Bernard A. Lung epithelium-specific proteins: characteristics and potential applications as markers. *Am J Respir Crit Care Med*. 1999;159(2):646-78.

[15] Ministry of Education, Culture, Sports, Science and Technology, and Ministry of Health, Welfare, and Work, Japan. Ethical Guidelines for Epidemiological Studies. June 17, 2002.

1  
2  
3  
4 <http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/ekigaku/0504sisin.html> (in Japanese)

5  
6 [16] He C, Morawska L, Taplin L. Particle emission characteristics of office printers. *Environ*  
7  
8  
9 *Sci Technol* 2007;41(17):6039-45.

10  
11 [17] Tang T, Hurras J, Gminski R, Mersch-Sundermann V. Fine and ultrafine particles emitted  
12  
13  
14  
15 from laser printers as indoor air contaminants in German offices. *Environ Sci Pollut Res Int*  
16  
17  
18 2012;19(9):3840-9.

19  
20 [18] McGarry P, Morawska L, He C, Jayaratne R, Falk M, Tran Q, Wang H. Exposure to  
21  
22  
23 particles from laser printers operating within office workplaces. *Environ Sci Technol*. 2011  
24  
25  
26 Aug 1;45(15):6444-52.

27  
28 [19] Khatri M, Bello D, Gaines P, Martin J, Pal AK, Gore R, Woskie S. Nanoparticles from  
29  
30  
31 photocopiers induce oxidative stress and upper respiratory tract inflammation in healthy  
32  
33  
34  
35 volunteers. *Nanotoxicology* 2013;7(5):1014-27.

36  
37 [20] Irie M1, Tamae K, Iwamoto-Tanaka N, Kasai H. Occupational and lifestyle factors and  
38  
39  
40 urinary 8-hydroxydeoxyguanosine. *Cancer Sci*. 2005 ;96(9):600-6.

41  
42 [21] Elango N, Kasi V, Vembhu B, Poornima JG. Chronic exposure to emissions from  
43  
44  
45 photocopiers in copy shops causes oxidative stress and systematic inflammation among  
46  
47  
48 photocopier operators in India. *Environ Health*. 2013;12(1):78.

49  
50 [22] Kasi V, Elango N, Ananth S, Vembhu B, Poornima JG. Occupational exposure to  
51  
52  
53 photocopiers and their toners cause genotoxicity. *Hum Exp Toxicol*. 2018;37(2):205-217.  
54  
55  
56

- 1  
2  
3  
4 [23] Yanagi N, Kitamura H, Mizuno M, Hata K, Uchiyama T, Kuga H, Matsushita T, Kurosak  
5  
6 S, Uehara M, Ogami A, Higashi T. A 4-Year Follow-up Cohort Study of the Respiratory  
7  
8 Functions in Toner-handling Workers. *Saf Health Work*. 2014;5(4):222-6.  
9  
10  
11 [24] Pirela SV, Martin J, Bello D, Demokritou P. Nanoparticle exposures from nano-enabled  
12  
13 toner-based printing equipment and human health: state of science and future research needs.  
14  
15 *Crit Rev Toxicol*. 2017;47(8):678-704.  
16  
17  
18 [25] Kitamura H, Terunuma N, Kurosaki S, Hata K, Masuda M, Kochi T, Yanagi N, Murase T,  
19  
20  
21 Ogami A, Higashi T. A cohort study using pulmonary function tests and x-ray examination in  
22  
23 toner-handling workers: cross-sectional and longitudinal analyses from 2003 to 2008. *Hum*  
24  
25 *Exp Toxicol*. 2015;34(4):345-56.  
26  
27  
28 [26] Ikegami K1, Hasegawa M, Ando H, Hata K, Kitamura H, Ogami A, Higashi T. A cohort  
29  
30  
31 study of the acute and chronic respiratory effects of toner exposure among handlers: a  
32  
33  
34 longitudinal analyses from 2004 to 2013. *Ind Health*. 2016 ;54(5):448-459.  
35  
36  
37 [27] Kitamura H, Terunuma N, Kurosaki S, Hata K, Masuda M, Kochi T, Yanagi N, Murase ,  
38  
39  
40  
41 Ogami A, Higashi T. A cohort study on self-reported respiratory symptoms of toner-handling  
42  
43 workers: cross-sectional and longitudinal analysis from 2003 to 2008. *Biomed Res Int*.  
44  
45  
46 2014;2014:826757.  
47  
48  
49  
50 [28] Landry A, Docherty P, Ouellette S, Cartier LJ. Causes and outcomes of markedly  
51  
52  
53 elevated C-reactive protein levels. *Can Fam Physician*. 2017;63(6):e316-e323.  
54  
55  
56

1  
2  
3  
4  
5  
6 **Figure legends**  
7  
8  
9  
10

11 **Fig. 1 The number of subjects analyzed based on the inclusion criteria of this study**  
12  
13  
14

15  
16  
17  
18  
19  
20 **Fig. 2. The exposure levels of toner-handling workers by year of measurement estimated**  
21  
22 **by personal exposure measurements.** The values are presented as the median and the 10th  
23  
24 and 90th percentiles (%ile) for personal exposure measurement data.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Background characteristics of the subjects according to the exposure category.**

Characteristics	Category of exposure condition						<i>p</i> <sup>†</sup>
	Control	Exposed*					
		Total	TPD	DDM	MTN	RCL	
Number surveyed	217	477	175	145	150	7	
Sex (M/F)	205/12	461/16	167/8	141/4	149/1	4/3	0.18
Age (years)	39.1(8.2)	34.1(8.1)	32.9(10.3)	35.4(6.5)	34.2(6.3)	32.4(7.6)	<0.0001
Height (cm)	170.1(6.6)	170.3(6.4)	169.0(6.1)	171.3(6.4)	171.4(6.4)	161.5(6.8)	0.63
BMI (kg/m <sup>2</sup> )	23.0(3.1)	23.0(3.7)	23.2(4.6)	22.4(2.6)	23.4(3.2)	19.9(1.5)	0.999
Smoking habit <sup>‡</sup>							0.026
Never	70(32)	150(31)	38(22)	69(48)	38(25)	5(71)	
Former	47(22)	67(14)	17(10)	26(18)	24(16)	0	
Current	100(46)	260(55)	120(68)	50(34)	88(59)	2(29)	
Personal exposure (mg/m <sup>3</sup> )							-
Number of samples		2042	1751	81	88	122	
Total dust							

10 <sup>th</sup> % ile	0.08	0.09	0.04	0.07	0.51
Median	0.49	0.50	0.08	0.17	1.46
90 <sup>th</sup> % ile	2.38	2.14	0.38	0.80	5.60
Respirable dust					
10 <sup>th</sup> % ile	0.03	0.03	0.03	0.03	0.02
Median	0.05	0.09	0.03	0.03	0.04
90 <sup>th</sup> % ile	0.36	0.35	0.04	0.15	0.64

\* TPD: toner production, DDM: machine design and development, MTN: maintenance, RCL: recycling, BMI: body mass index

†Probability under the hypothesis that there are no differences between the control group and the exposed group as a whole.

‡Percentage of column total in parentheses.

Values are presented as the number of subjects for sex and smoking habit and the arithmetic mean (standard deviations) for age, height, and BMI at the baseline survey.

**Table 2. The comparison of the baseline status in select biomedical indices at the point of the first examination for each subject between the exposed subjects as a whole and the controls**

Biomedical indices	Univariate analysis			Multivariate analysis	
	Exposed	Controls	<i>p</i> *	OR <sup>†</sup>	95%CI <sup>†</sup>
Respiratory symptoms <sup>‡</sup>					
Cough #1 (7A)	19.4	14.8	0.14	1.35	(0.85-2.14)
Cough #2 (7B)	14.8	11.1	0.19	1.41	(0.84-2.37)
Chronic cough (7E)	5.5	4.2	0.46	1.6	(0.70-3.64)
Phlegm #1 (8A)	23.7	20.4	0.34	1.23	(0.81-1.87)
Phlegm #2 (8B)	13.5	10.7	0.29	1.45	(0.85-2.48)
Chronic phlegm (8E)	8.9	4.2	0.03	2.62	(1.20-5.70)
Exacerbation (9A)	10.5	7	0.14	1.56	(0.84-2.91)
Wheeze #1 (10A1)	9.5	5.6	0.09	1.51	(0.76-2.99)
Wheeze #2 <sup>§</sup> (10A2)	2.7	0	0.01	-	-
Chronic Wheeze (10A3)	0	0	-	-	-
Breathlessness #1 (13A)	9.7	11.6	0.45	1	(0.58-1.73)

Breathlessness #2 <sup>§</sup> (13B)	2.2	1.4	0.76	2.27	(0.58-8.89)
Breathlessness #3 <sup>§</sup> (13C)	0.4	0.9	0.59	0.96	(0.13-7.20)
Biomarker abnormality					
CRP	12.0	6.0	0.02	2.02	(1.05-3.88)
IgE	31.7	20.8	0.003	1.66	(1.12-2.48)
8OHdG <sup>§</sup>	1.1	1.8	0.47	0.68	(0.17-2.78)
KL6 <sup>§</sup>	0.4	0	1	-	-
SPD	3.2	3.4	0.89	0.91	(0.35-2.37)
Reduced pulmonary function					
FVC	6.5	6.0	0.76	1.00	(0.49-2.00)
FEV1	6.1	2.8	0.06	2.09	(0.83-5.27)
FEV1/FVC <sup>§</sup>	2.1	5.1	0.03	0.44	(0.18-1.09)
Chest X-ray findings					
Fibrotic change $\geq 1/1$	0	0	1	-	-
Non-specific findings	3.4	1.8	0.27	2.47	(0.78-7.81)

\* Probability under the hypothesis that there are no differences between the control group and exposed group as a whole examined by the chi-squared test or Fisher's exact probability method.



1  
2  
3  
4 † Odds ratio (OR) and its 95% confidence intervals (95% CI) of the exposed group to the  
5  
6 control group, regarding the positive findings at the baseline survey  
7

8  
9 ‡ The ATS-DLD-78A questionnaire code is shown in the parentheses  
10

11 § Fisher's exact probability method was applied.  
12

13  
14 # Grade of symptom severity: cough #1 and phlegm #1, usually having the symptom; cough  
15  
16 #2 and phlegm #2, 4 to 6 times a day on 4 or more days a week; wheeze #1, when having a  
17  
18 cold; wheeze #2, occasionally apart from cold; breathlessness #1, when hurrying on the level  
19  
20 or walking up a slight hill; breathlessness #2, having to walk slower than people your age on  
21  
22 the level; breathlessness #3, having to stop for breath when walking at your own pace.  
23  
24  
25  
26  
27

28  
29 The figures in the column of prevalence represent the proportion of subjects with symptoms  
30  
31 or positive findings in each index. The results of multivariate analyses were adjusted for the  
32  
33 age and smoking status of the subjects. Body mass index was also used as an adjustment  
34  
35 factor in the case of CRP.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Table 3. A comparison of the cumulative frequency of incidence in select biomedical indices associated with lung fibrotic changes that newly emerged during the follow-up period**

	Univariate analysis			Multivariate analysis			
	Incidence			Logistic regression model			
	Total			Total	TPD	DDM	MTN
Exposed	Controls	<i>p</i> *	OR(95%CI) <sup>†</sup>	OR (95%CI) <sup>†</sup>	OR (95%CI) <sup>†</sup>	OR (95%CI) <sup>†</sup>	
Respiratory symptoms <sup>‡</sup>							
Chronic cough (7E)	11.3	6.3	0.04	2.26(1.13-4.53)	1.88(0.82-4.31)	2.70(1.21-5.99)	2.31(1.01-5.25)
Chronic phlegm (8E)	14.0	9.6	0.12	1.6(0.91-2.83)	1.46(0.74-2.88)	1.65(0.81-3.37)	1.68(0.83-3.40)

Breathlessness #2 (13B)	6.0	4.7	0.48	1.69(0.73-3.94)	1.51(0.54-4.19)	0.94(0.27-3.25)	2.62(1.00-6.87)
Serum biomarkers							
KL6§	2.1	1.8	1.00	1.27(0.38-4.29)	2.09(0.54-8.05)	0.44(0.05-4.09)	1.25(0.26-5.94)
SPD	2.4	2.4	1.00	1.06(0.34-3.28)	0.87(0.21-3.54)	1.62(0.40-6.48)	0.94(0.21-4.24)
Pulmonary function							
FVC	15.3	13.2	0.50	1.22(0.73-2.05)	2.60(1.44-4.71)	0.54(0.24-1.21)	0.84(0.42-1.68)
FEV1	11.4	8.5	0.26	1.38(0.76-2.49)	2.43(1.24-4.76)	0.68(0.27-1.69)	1.19(0.55-2.57)
FEV1/FVC	9.9	6.8	0.20	1.59(0.81-3.09)	1.88(0.87-4.09)	1.16(0.48-2.85)	1.72(0.77-3.85)
Chest X-ray							
Non-specific findings	5.6	5.2	0.8	1.39(0.65-2.97)	1.38(0.53-3.59)	1.75(0.70-4.37)	0.98(0.34-2.80)

TPD: toner production, DDM: machine design and development, MTN: maintenance, RCL: recycling

1  
2  
3  
4  
5  
6 \* Probability under the hypothesis that there are no differences between the control group and exposed group as a whole examined by the  
7  
8 chi-squared test or Fisher's exact probability method  
9

10  
11 † Odds ratio (OR) and its 95% confidence intervals (95% CI) of the exposed group to the control group, regarding the newly emerging  
12  
13 abnormalities of biomedical indices  
14  
15

16  
17 ‡ The ATS-DLD-78A questionnaire code is shown in the parentheses.  
18

19  
20 § Fisher's exact probability method was applied.  
21

22  
23 # Grade of the severity of the symptom  
24

25  
26 The figures in the column of incidence represent the proportion of subjects starting to show symptoms or positive findings during the follow-up  
27  
28 period among those who did not have the symptom or positive finding at baseline. The results of multivariate analyses were adjusted for the age  
29  
30 and smoking status of the subjects.  
31  
32  
33  
34  
35  
36  
37  
38  
39

**Table 4.** Annual decline in spirometric indices according to exposure category.

	Category of exposure condition (number of subjects)						Statistical test of the	
	Control	Exposed*					mean values†	
		Total	TPD	DDM	MTN	RCL	<i>p</i>	
Spirometric indices	(N=217)	(N=477)	(N=175)	(N=145)	(N=150)	(N=7)	Unadjusted	Adjusted‡
$\Delta$ FVC/HT <sup>2</sup> (ml/m <sup>2</sup> )	-6.2(21.4)	-4.0(19.1)	-0.7(25.8)	-2.5(12.5)	-9.0(14.3)	-5.8(13.3)	0.19	0.50
$\Delta$ FEV1/HT <sup>2</sup> (ml/m <sup>2</sup> )	-8.8(16.3)	-7.5(13.9)	-6.5(16.3)	-7.3(10.7)	-9.0(12.5)	-6.7(32.6)	0.33	0.30

\* TPD: Toner production, DDM: Machine design and development, MTN: Maintenance, RCL: Recycling

† Comparison between the control and the exposed as a whole

‡ Adjusted for age, sex, and smoking habit at the baseline.

Values are the arithmetic means and standard deviations at the point of baseline survey.

For peer review only



1			
2			
3			
4			
5			
6	Breathlessness #1 (13A) <sup>§</sup>	1.59(1.17-2.16)	
7			
8			
9	Breathlessness #2†(13B) <sup>§</sup>	2.64(1.36-5.12)	
10			
11	Breathlessness #3‡(13C) <sup>§</sup>	5.62(1.51-20.85)	
12			
13			
14	CRP abnormality		1.32(1.17-1.49)
15			
16			
17	5 SPD abnormality	4.10(1.15-14.58)	
18			
19			
20	Reduced FVC	3.13(1.09-8.97)	
21			
22			
23	Reduced FEV1	3.82(1.38-10.58)	
24			
25			
26	Reduced FEV1/FVC	3.92(1.20-12.87)	2.11(1.27-3.52)
27			
28			
29	Non-specific X-ray		1.59(1.06-2.38)
30			
31	10 findings		
32			
33			
34			
35			
36			
37	* An analysis of the prevalence at baseline.		
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			



1  
2  
3  
4  
5  
6 † An analysis of the new incidence during the follow-up observation  
7

8 ‡ Odds ratio (OR) and its 95% confidence intervals (95% CI) of the exposed group to the control group, regarding the prevalence and incidence  
9  
10 of biomedical indices.  
11  
12

13 § The ATS-DLD-78A questionnaire code is shown in the parentheses.  
14  
15

16  
17 5 # Grade of the severity of the symptom  
18  
19

20 Values are presented as the OR (95% CI) estimated using the logistic regression models shown in Tables 3 and 4. Only statistically significant  
21  
22 results are shown.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47






Fig. 1 The number of subjects analyzed based on the inclusion criteria of this study

119x90mm (300 x 300 DPI)



90x112mm (300 x 300 DPI)

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies***

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6-7
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	8-10
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	10-15
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	10-15
Bias	9	Describe any efforts to address potential sources of bias	9, 10-13
Study size	10	Explain how the study size was arrived at	8-9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	15-17
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	17
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	8-9
		(e) Describe any sensitivity analyses	22-23, 48-50
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-9, 19
		(b) Give reasons for non-participation at each stage	8-9, 19
		(c) Consider use of a flow diagram	51(Fib.1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	19-20, 38-39, 52(Fig.2)
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	19
Outcome data	15*	Report numbers of outcome events or summary measures over time	21-22, 43-47
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	21-22, 43-47
		(b) Report category boundaries when continuous variables were categorized	12, 14
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	22-23, 43-45, 48-50
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	27, 31
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	29-30
Generalisability	21	Discuss the generalisability (external validity) of the study results	
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	32

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).